Nicotinic receptor compounds

ABSTRACT

Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with United States Government support underDA012001 awarded by the National Institutes of Health. The United StatesGovernment has certain rights in the invention.

FIELD OF THE INVENTION

The present application is directed to various compounds and methods ofpreparation of compounds that are capable of functioning as agonists orantagonists of the nicotinic receptors. The application is also directedto pharmaceutical compositions comprising one or more of thesecompounds, which may also comprise one or more additional therapeuticagents. It is further directed to methods of treatment of variousconditions that may be responsive to modulation of the activation ofnicotinic receptors, including methods directed to smoking cessation.

BACKGROUND OF THE INVENTION

Tobacco use is the leading preventable cause of disease, disability, anddeath in the United States. Cigarette smoking results in more than400,000 premature deaths in the United States each year, accounting forabout 1 in every 5 deaths according to the Centers for Disease Control2008 Smoking and Tobacco Use Fact Sheet. Statistics from the U.S.Department of Health and Human Services show that, on average, adultswho smoke die 14 years earlier than nonsmokers.

Cigarette smoking accounts for about one-third of all cancers, including90% of lung cancer cases. Smoking also causes lung diseases such aschronic bronchitis and emphysema and increases the risk of stroke, heartattack, vascular disease, and aneurysm. In spite of these documentedconnections between tobacco use and disease, a large number of peoplecontinue to use tobacco products. In 2008, 28.6% of the U.S. population12 years of age and older (70.9 million people) had used a tobaccoproduct at least once in the month prior to being interviewed. Thisfigure includes 3.1 million young people aged 12-17 (12.4% of this agegroup).

Nicotine is considered the main psychoactive component in tobacco smokethat causes people to use and continue to use tobacco products. Thepharmacological and behavioral effects result from interaction withdifferent nicotinic acetylcholine receptor (nAChR) subtypes. Thesubtypes are either homo or hetero pentameric ion channels, consistingof different combinations of genetically distinct subunits, (α1,α2-αa10, β1-β4, γ, δ, ε). The predominant nAChR subtypes found in thebrain are thought to be heteromeric α4β2 nAChR or homomeric α7-nAChR;however, appreciable amounts of α3β4* and α6β2* nAChRs (where the *indicate that other subunits are known or possible assembly partnerswith those specified) also are in brain regions implicated in reward anddrug dependence.

Nicotine exposure can stimulate activity of somatodendritic nAChRs toalter neuronal electrical activity and neurotransmitter release as aconsequence of neuronal activation. However, by acting at nAChRspositioned on nerve terminals, nicotine also can increaseneurotransmitter release as a consequence of local depolarization of thenerve terminal membrane potential and/or calcium ion mobilization interminals. The integration of these effects is likely to contribute tonicotine's actions, including those that are presumably involved in itsreinforcement of tobacco product use, such as effects in monoaminergicreward pathways.

Even though nicotine dependence has a huge impact on global health,pharmacotherapies for treating tobacco use are limited. Currenttreatments include nicotine-replacement therapies (NRTs), bupropion, andvarenicline. Since only about one-fifth of smokers are able to maintainlong-term (12 months) abstinence with any of the presentpharmacotherapies, there is a need in the art for new and improvedpharmaceutical compositions for treating drug addiction.

It is thought to be possible that specific subtypes of nAChRs mediatespecific functions, especially as this relates to nicotine addiction.Thus, it would be beneficial to provide a variety of ligands that bindwith high affinity and selectivity for each nAChR subtype. Both agonistsand antagonists of the various subtypes of nAChRs are desirable sincethe role of nAChRs in addiction is not known. A number of compoundshaving activity at one or more nAChR subtype have been studied aspotential smoking cessation agents. For example, epibatidine is anicotinic agonist whose biological effects appear to be mediated by α₄β₂nAChRs. However, epibatidine exhibits toxicity that precludes its use inhumans. Some analogs of epibatidine have been prepared and studied in anattempt to maintain the activity of epibatidine but eliminate itstoxicity (see for example, U.S. Pat. No. 6,538,010 and U.S. Pat. No.7,615,567, incorporated herein by reference). However, there exists aneed for additional such analogs, which may be potent and/or selectivefor specific nAChRs (e.g., the α₄β₂ nAChR), and which could thereforeprovide alternative therapeutics for the treatment of nicotinedependence.

BRIEF SUMMARY OF THE INVENTION

The present invention relates generally to compounds that may be usefulas agonists and/or antagonists of the nicotine receptors. It alsorelates to pharmaceutical formulations of such compounds and to methodsof using such compounds or formulations thereof to treat nicotinedependence or other various conditions that may be responsive tomodulation of the activation of nicotinic receptors.

In one aspect of the invention is provided a compound according to thefollowing structure:

wherein:

-   -   A is —R, —N(R)₂, —C(═NR)N(R)₂, or —OR,    -   each R is, independently, H, alkyl, alkenyl, alkynyl, aryl, or        aralkyl;    -   each X is, independently, H, halo, alkyl, alkenyl, alkynyl,        aralkyl, —OR, —CH₂—CO₂R, —C(O)R, —CO₂R, —N(R)₂, —NR-C(O)R,        —C(O)N(R)₂, —NR—CO₂R, —SO₃CF₃, —NO₂, —N₃, —CF₃, —CH═CHY, or —CN;    -   Y is halo;    -   n is an integer from 0-3; and    -   R₁ is an optionally substituted heteroaryl;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, a compound is provided wherein R₁ is selectedfrom the group consisting of optionally substituted thiophene, pyrrole,furan, oxazole, pyrazole, imidazole, thiazole, purine, triazole,thiadiazole, pyridine, quinoline, isoquinoline, phenanthrine,5,6-cycloheptenopyridine, pyridazine, cinnoline, phthalazine, pyrazine,pyrimidine, quinazoline, and 1,3,5-triazine. In certain embodiments, R₁is pyrimidine. For example, in one particular embodiment, R₁ ispyrimidine, X is halo, n=1, and A is H.

In certain embodiments, a compound of the following structure isprovided:

wherein:

-   -   each X is, independently, H or a halo substituent;    -   n is an integer from 0-3;    -   each R₂ is independently selected from the group consisting of        H, C1-6 alkoxy, amino, halo, hydroxyl, amide, CN, CH₃SO₂, and        CF₃SO₂; and    -   m is an integer from 0-4;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In other certain embodiments, a compound of the following structure isprovided:

wherein:

-   -   each X is, independently, H or a halo substituent;    -   n is an integer from 0-3;    -   each R₂ is independently selected from the group consisting of        H, C1-6 alkoxy, amino, halo, hydroxyl, amide, CN, CH₃SO₂, and        CF₃SO₂; and    -   m is an integer from 0-4;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In further embodiments, a compound of the following structure isprovided:

wherein:

-   -   each X is, independently, H or a halo substituent; n is an        integer from 0-3;    -   each R₂ is independently selected from the group consisting of        H, C1-6 alkoxy, amino, halo, hydroxyl, amide, CN, CH₃SO₂, and        CF₃SO₂; and    -   p is an integer from 0-3;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In still further embodiments of the invention, a compound of thefollowing structure is provided:

wherein:

-   -   each X is, independently, H or a halo substituent;    -   n is an integer from 0-3;    -   each R₂ is independently selected from the group consisting of        H, C1-6 alkoxy, amino, halo, hydroxyl, amide, CN, CH₃SO₂, and        CF₃SO₂; and    -   p is an integer from 0-3;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, specific compounds are provided, wherein thecompounds are selected from the group consisting of:

-   2-exo-[2′-Fluoro-3′-(2-fluoropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(2-chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(6-fluoropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(6-chloropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(pyridin-4-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(pyridin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(6-methoxypyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2′-Fluoro-3′-(2″-amino-5″-pyridinyl)deschloroepibatidine;-   2-exo-[2′-Fluoro-3′-(2-methoxypyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-Fluoro-3-(2′-amino-4′-pyridinyl)deschloroepibatidine;-   2-exo-[3′-(2-Chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(2-Fluoropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(Pyridin-4-yl) -5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(2-Aminopyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(2-Methoxypyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(pyrimidin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Chloro-3′-(pyrimidin-5-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(Pyrimidin-5-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(pyridazin-4-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Chloro-3′-(pyridazin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[3′-(Pyridazin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(thiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-fluorothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-ehlorothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-aminothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-methoxythiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(4-fluorothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(4-chlorothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(4-aminothiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(4-methoxythiophen-2-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(thiophen-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-fluorothiophen-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-chlorothiophen-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-aminothiophen-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(5-methoxythiophen-3-yl)-5′-pyridinyl]-7-azabicyclo    [2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(6-fluoropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-exo-[2′-Fluoro-3′-(6-chloropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane;-   2-Fluoro-3-(2′-fluoro-4′-pyridinyl)deschloroepibatidine;-   2-Fluoro-3-(2′-chloro-4′-pyridinyl)deschloroepibatidine; and-   2-Fluoro-3-(4′-pyridinyl)deschloroepibatidine.

In another aspect of the invention is provided a method for treating ordelaying the progression of disorders that are alleviated by agonizingor antagonizing the nicotinic acetylcholine receptor by administering atherapeutically effective amount of at least one compound of theinvention. In some embodiments, the disorder to be treated may beaddiction (e.g., nicotine dependence), Alzheimer's disease, Parkinson'sdisease, pain (analgesic activity), depression, Tourette's syndrome,inflammatory bowel syndrome, schizophrenia, anxiety, epilepsy,attention-deficit hyperactivity disorder, ulcerative colitis, orobesity. In a still further aspect of the invention is provided apharmaceutical composition comprising a compound of the invention andone or more pharmaceutically acceptable carriers.

DETAILED DESCRIPTION OF THE INVENTION

Many modifications and other embodiments of the inventions set forthherein will come to mind to one skilled in the art to which theseinventions pertain having the benefit of the teachings presented herein.Therefore, it is to be understood that the inventions are not to belimited to the specific embodiments disclosed and that modifications andother embodiments are intended to be included within the scope of theappended claims. Although specific terms are employed herein, they areused in a generic and descriptive sense only and not for purposes oflimitation. As used in the specification, and in the appended claims,the singular forms “a”, “an”, “the”, include plural referents unless thecontext clearly dictates otherwise.

The present invention provides compounds that may function as agonistsand/or antagonists of the nicotinic acetylcholine receptor (nAChR). Theinvention also provides methods of preparation and pharmaceuticalcompositions thereof. It also provides methods for using such compoundsto treat a variety of disorders that may be responsive to modulation ofthe activation of nicotinic receptors (i.e., activation of the receptoror partial or complete deactivation of the receptor). Thus, thecompounds of the present invention may interact with nicotinicreceptors; for example, they may act as agonists and/or antagonists ofthe nicotinic receptors. In certain embodiments, the compounds may actas partial agonists, which may have both agonist and antagonistactivity. In particular, the compositions and methods can be used totreat nicotine dependence (e.g., aid in smoking cessation). In someembodiments, treatment can comprise the use of a compound of the presentinvention as a single active agent. In other embodiments, treatment cancomprise the use of a compound of the present invention in combinationwith one or more further active agents. The specific pharmaceuticalcomposition (or compositions) used in the invention, and the methods oftreatment provided by the invention, are further described below.

Definitions

The term “alkyl” as used herein means saturated straight, branched, orcyclic hydrocarbon groups. In particular embodiments, alkyl refers togroups comprising 1 to 10 carbon atoms (“C1-10 alkyl”). In furtherembodiments, alkyl refers to groups comprising 1 to 8 carbon atoms(“C1-8 alkyl”), 1 to 6 carbon atoms (“C1-6 alkyl”), 1 to 4 carbon atoms(“C1-4 alkyl”), or 1 to 3 carbon atoms (“C1-3 alkyl”). In otherembodiments, alkyl refers to groups comprising 3-10 carbon atoms (“C3-10alkyl”), 3-8 carbon atoms (“C3-8 alkyl”), or 3-6 carbon atoms (“C3-6alkyl”). In specific embodiments, alkyl refers to methyl, ethyl, propyl,isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl,isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl,3-methylpentyl, 2,2-dimethybutyl, and 2,3-dimethylbutyl. Substitutedalkyl includes alkyl substituted with one or more moieties selected fromthe group consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl(e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); hydroxyl;amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy;nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid;phosphate; and phosphonate.

The term “alkenyl” as used herein means alkyl moieties wherein at leastone saturated C—C bond is replaced by a double bond. In particularembodiments, alkenyl refers to groups comprising 2 to 10 carbon atoms(“C2-10 alkenyl”). In further embodiments, alkenyl refers to groupscomprising 2 to 8 carbon atoms (“C2-8 alkenyl”), 2 to 6 carbon atoms(“C2-6 alkenyl”), or 2 to 4 carbon atoms (“C2-4 alkenyl”). In specificembodiments, alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl,1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl,4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl.

The term “alkynyl” as used herein means alkyl moieties wherein at leastone saturated C—C bond is replaced by a triple bond. In particularembodiments, alkynyl refers to groups comprising 2 to 10 carbon atoms(“C2-10 alkynyl”). In further embodiments, alkynyl refers to groupscomprising 2 to 8 carbon atoms (“C2-8 alkynyl”), 2 to 6 carbon atoms(“C2-6 alkynyl”), or 2 to 4 carbon atoms (“2-4 alkynyl”). In specificembodiments, alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl,2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl,1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl.

The term “alkoxy” as used herein means straight or branched chain alkylgroups linked by an oxygen atom (i.e., —O-alkyl), wherein alkyl is asdescribed above. In particular embodiments, alkoxy refers tooxygen-linked groups comprising 1 to 10 carbon atoms (“C1-10 alkoxy”).In further embodiments, alkoxy refers to oxygen-linked groups comprising1 to 8 carbon atoms (“C1-8 alkoxy”), 1 to 6 carbon atoms (“C1-6alkoxy”), 1 to 4 carbon atoms (“C1-4 alkoxy”) or 1 to 3 carbon atoms(“C1-3 alkoxy”).

The term “aryl” as used herein means a stable monocyclic, bicyclic, ortricyclic carbon ring of up to 8 members in each ring, wherein at leastone ring is aromatic as defined by the Mickel 4n+2 rule.

The term “heteroaryl” as used herein means an aryl group containing fromone or more (particularly one to four) non-carbon atom(s) (particularlyN or S) or a combination thereof, which heteroaryl group is optionallysubstituted at one or more carbon or nitrogen atom(s) with alkyl, —CF₃,phenyl, benzyl, or thienyl, or a carbon atom in the heteroaryl grouptogether with an oxygen atom form a carbonyl group, or which heteroarylgroup is optionally fused with a phenyl ring. Heteroaryl rings may alsobe fused with one or more cyclic hydrocarbon, heterocyclic, aryl, orheteroaryl rings. Heteroaryl includes, but is not limited to, 5-memberedheteroaryls having one hetero atom (e.g., thiophenes, pyrroles, furans);5 membered heteroaryls having two heteroatoms in 1,2 or 1,3 positions(e.g., oxazoles, pyrazoles, imidazoles, thiazoles, purines); 5-memberedheteroaryls having three heteroatoms (e.g., triazoles, thiadiazoles);5-membered heteroaryls having 3 heteroatoms; 6-membered heteroaryls withone heteroatom (e.g., pyridine, quinoline, isoquinoline, phenanthrine,5,6-cycloheptenopyridine); 6-membered heteroaryls with two heteroatoms(e.g., pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines,quinazolines); 6-membered heretoaryls with three heteroatoms (e.g.,1,3,5-triazine); and 6-membered heteroaryls with four heteroatoms.“Substituted heteroaryl” means a heteroaryl having one or morenon-interfering groups as substituents.

The term “halo” or “halogen” as used herein means fluorine, chlorine,bromine, or iodine.

The term “alkylthio” as used herein means a thio group with one or morealkyl substituents, where alkyl is defined as above.

The term “acylamido” refers to an amide group with one or more acylsubstituents, where acyl is as defined below.

The term “acyl” as used herein means a group formed by removing thehydroxyl group from a carboxylic acid, in which the non-carbonyl moietyof the group is selected from straight, branched, or cyclic alkyl orlower alkyl; alkoxyalkyl including methoxymethyl; aralkyl includingbenzyl; aryloxyalkyl such as phenoxymethyl; aryl including phenyloptionally substituted with halogen, C1-6 alkyl or C1-6 alkoxy;sulfonate esters such as alkyl or aralkyl sulphonyl includingmethanesulfonyl; mono-, di-, or triphosphate ester; trityl ormonomethoxytrityl; substituted benzyl; trialkylsilyl such asdimethyl-t-butylsilyl or diphenylmethylsilyl.

The terms “aralkyl” and “arylalkyl” as used herein mean an aryl group asdefined above linked to the molecule through an alkyl group as definedabove.

The term “amino” as used herein means a moiety represented by thestructure NR₂, and includes primary amines, and secondary and tertiaryamines substituted by alkyl (i.e., alkylamino). Thus, R₂ may represent,for example, two hydrogen atoms, two alkyl moieties, or one hydrogenatom and one alkyl moiety.

The term “cycloalkyl” means a non-aromatic, monocyclic or polycyclicring comprising carbon and hydrogen atoms. Substituted cycloalkylincludes alkyl substituted with one or more moieties selected from thegroup consisting of halo (e.g., Cl, F, Br, and I); halogenated alkyl(e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); hydroxyl;amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy;nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid;phosphate; and phosphonate.

“Optionally substituted” in reference to a substituent group refers tosubstituent groups optionally substituted with one or more moieties, forexample, those selected from the group consisting of optionallysubstituted C1-10 alkyl (e.g., optionally substituted C1-6 alkyl);optionally substituted C1-10 alkoxy (e.g., optionally substituted C1-6alkoxy); optionally substituted C2-10 alkenyl; optionally substitutedC2-10 alkynyl; optionally substituted C6-C12 aryl; aryloxy; optionallysubstituted heteroaryl; optionally substituted heterocycle; halo (e.g.,Cl, F, Br, and I); hydroxyl; halogenated alkyl (e.g., CF₃, 2-Br-ethyl,CH₂F, CH₂CF₃, and CF₂CF₃); amino (e.g., NH₂, NR₁₂H, and NR₁₂R₁₃);alkylamino; arylamino; acyl; amido; CN; NO₂; N₃; CH₂OH; CONH₂;CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂; NHCO₂R₁₂; C1-3 alkylthio; sulfate;sulfonic acid; sulfonate esters such as alkyl or aralkyl sulfonyl,including methanesulfonyl; phosphonic acid; phosphate; phosphonate;mono-, di-, or triphosphate esters; trityl or monomethoxytrityl; R₁₂SO;R₁₂SO₂; CF₃S; and CF₃SO₂; trialkylsilyl such as dimethyl-t-butylsilyl ordiphenylmethylsilyl; and R₁₂ and R₁₃ are each independently selectedfrom H or optionally substituted C1-10 alkyl.

The term “analogue,” used interchangeably with the term “analog” herein,means a compound in which one or more individual atoms or functionalgroups have been replaced, either with a different atom or a differentfunctional, generally giving rise to a compound with similar properties.

The term “derivative” as used herein means a compound that is formedfrom a similar, beginning compound by attaching another molecule or atomto the beginning compound. Further, derivatives, according to theinvention, encompass one or more compounds formed from a precursorcompound through addition of one or more atoms or molecules or throughcombining two or more precursor compounds.

The term “prodrug” as used herein means any compound which, whenadministered to a mammal, is converted in whole or in part to a compoundof the invention.

The term “active metabolite” as used herein means a physiologicallyactive compound which results from the metabolism of a compound of theinvention, or a prodrug thereof, when such compound or prodrug isadministered to a mammal.

The terms “therapeutically effective amount” or “therapeuticallyeffective dose” as used herein are interchangeable and mean aconcentration of a compound according to the invention, or abiologically active variant thereof, sufficient to elicit the desiredtherapeutic effect according to the methods of treatment describedherein.

The term “pharmaceutically acceptable carrier” as used herein means acarrier that is conventionally used in the art to facilitate thestorage, administration, and/or the healing effect of a biologicallyactive agent.

The term “intermittent administration” as used herein meansadministration of a therapeutically effective dose of a compositionaccording to the invention, followed by a time period of discontinuance,which is then followed by another administration of a therapeuticallyeffective dose, and so forth.

Active Agents

The present invention provides compounds, methods of preparation of thecompounds, pharmaceutical compositions, and methods of treatment ofvarious conditions using such compounds and pharmaceutical compositions.

In certain embodiments, a compound of Formula I is provided:

wherein:

-   -   A is —R, —N(R)₂, —C(═NR)N(R)₂, or —OR,    -   each R is, independently, H, alkyl, alkenyl, alkynyl, aryl, or        aralkyl;    -   each X is, independently, H, halo, alkyl, alkenyl, alkynyl,        aralkyl, —OR, —CH₂—CO₂R, —C(O)R, —CO₂R, —N(R)₂, —NR—C(O)R, amide        (i.e., —C(O)N(R)₂), —NR—CO₂R, —SO₃CF₃, —NO₂, —N₃, —CF₃, —CH═CHY,        or —CN;    -   Y is halo;    -   n is an integer from 0-3; and    -   R₁ is an optionally substituted heteroaryl;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In certain embodiments, n=1. In specific embodiments, the pyridyl ringis substituted at the carbon between the N and the carbon to which R₁ isattached. In certain embodiments, the substituent X is H, Cl, or F. Incertain embodiments, the optionally substituted heteroaryl has one ormore substituents. Substituents may include, but are not limited to,optionally substituted C1-10 alkyl (e.g., optionally substituted C1-6alkyl); optionally substituted C1-10 alkoxy (e.g., optionallysubstituted C1-6 alkoxy); optionally substituted C2-10 alkenyl;optionally substituted C2-10 alkynyl; optionally substituted C6-C12aryl; aryloxy; optionally substituted heteroaryl; optionally substitutedheterocycle; halo (e.g., Cl, F, Br, and I); hydroxyl; halogenated alkyl(e.g., CF₃, 2-Br-ethyl, CH₂F, CH₂CF₃, and CF₂CF₃); amino (e.g., NH₂,NR₁₂H, and NR₁₂R₁₃); alkylamino; arylamino; acyl; amido; CN; NO₂; N₃;CH₂OH; CONH₂; CONR₁₂R₁₃; CO₂R₁₂; CH₂OR₁₂; NHCOR₁₂; NHCO₂R₁₂; C1-3alkylthio; sulfate; sulfonic acid; sulfonate esters such as alkyl oraralkyl sulfonyl, including methanesulfonyl; phosphonic acid; phosphate;phosphonate; mono-, di-, or triphosphate esters; trityl ormonomethoxytrityl; R₁₂R₁₃NSO₂ (including H₂NSO₂); R₁₂SO; R₁₂SO₂; CF₃S;and CF₃SO₂; trialkylsilyl such as dimethyl-t-butylsilyl ordiphenylmethylsilyl; and R₁₂ and R₁₃ are each independently selectedfrom H or optionally substituted C1-10 alkyl. In specific embodiments,the optionally substituted heteroaryl has one substituent. In somepreferred embodiments, the optionally substituted heteroaryl has one ormore halo (e.g., F or Cl) substituents. In some preferred embodiments,the optionally substituted heteroaryl has one or more aminosubstituents. In some preferred embodiments, the optionally substitutedheteroaryl has one or more alkoxy substituents. The optionalsubstituents on the heteoraryl may further be substituted with any typeof substituent as indicated above.

In certain embodiments, R₁ is an optionally substituted pyridine. Thenitrogen of the pyridine may be at any position on the ring. Forexample, in some embodiments, the compound may be a compound of FormulaIa:

wherein:

-   -   each X is, independently, any of the substituents listed for X        in Formula I, with preferred X substituents being H or halo;    -   n is an integer from 0-3;    -   each R₂ is, independently, any of the substituents set forth        above, with preferred R₂ substituents H, C1-6 alkoxy, amino,        halo, hydroxyl, amide, CN, CH₃SO₂, and CF₃SO₂; and    -   m is an integer from 0-4;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In some preferred embodiments of Formula Ia, m=1. In certain specificembodiments wherein m=1, the R₂ substituent is located on the carbonadjacent to the N of the ring and para to the remainder of the molecule.

In some other embodiments, the compound may be a compound of Formula Ib:

wherein:

-   -   each X is, independently, any of the substituents listed for X        in Formula I, with preferred X substituents being H or halo;    -   n is an integer from 0-3;    -   each R₂ is, independently, any of the substituents set forth        above, with preferred R₂ substituents H, C1-6 alkoxy, amino,        halo, hydroxyl, amide, CN, CH₃SO₂, and CF₃SO₂; and    -   m is an integer from 0-4;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In preferred embodiments of Formula Ib, m=1. In certain specificembodiments wherein m=1, the R₂ substituent is located on a carbonadjacent to the N.

In certain embodiments, R₁ is an optionally substituted thiophene. Thesulfur atom may be located at any position on the ring. For example, insome embodiments, the compound may be a compound of Formula Ic:

wherein:

-   -   each X is, independently, any of the substituents listed for X        in Formula I, with preferred X substituents being H or halo;    -   n is an integer from 0-3;    -   each R₂ is, independently, any of the substituents set forth        above, with preferred R₂ substituents H, C1-6 alkoxy, amino,        halo, hydroxyl, amide, CN, CH₃SO₂, and CF₃SO₂; and    -   p is an integer from 0-3;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In some preferred embodiments of Formula Ic, p=1. In certain specificembodiments wherein p=1, the R₂ substituent is located on the carbonadjacent to the S. In certain specific embodiments wherein p=1, the R₂substituent is located on the carbon that is neither adjacent to the Snor to the remainder of the molecule.

In some other embodiments, the compound may be a compound of Formula Id:

wherein:

-   -   each X is, independently, any of the substituents listed for X        in Formula I, with preferred X substituents being H or halo;    -   n is an integer from 0-3;    -   each R₂ is, independently, any of the substituents set forth        above, with preferred R₂ substituents H, C1-6 alkoxy, amino,        halo, hydroxyl, amide, CN, CH₃SO₂, and CF₃SO₂; and    -   p is an integer from 0-3;

or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug,or isomer thereof.

In some preferred embodiments of Formula Id, p=1. In certain specificembodiments wherein p=1, the R₂ substituent is located on the carbonadjacent to the S but not to the remainder of the molecule.

In some embodiments of the present invention, therapeutically inactiveprodrugs are provided. Prodrugs are compounds which, when administeredto a mammal, are converted in whole or in part to a compound of theinvention. In most embodiments, the prodrugs are pharmacologically inertchemical derivatives that can be converted in vivo to the active drugmolecules to exert a therapeutic effect. Any of the compounds describedherein can be administered as a prodrug to increase the activity,bioavailability, or stability of the compound or to otherwise alter theproperties of the compound. Typical examples of prodrugs includecompounds that have biologically labile protecting groups on afunctional moiety of the active compound. Prodrugs include, but are notlimited to, compounds that can be oxidized, reduced, aminated,deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed,alkylated, dealkylated, acylated, deacylated, phosphorylated, and/ordephosphorylated to produce the active compound.

A number of prodrug ligands are known. In general, alkylation,acylation, or other lipophilic modification of one or more heteroatomsof the compound, such as a free amine or carboxylic acid residue, mayreduce polarity and allow for the compound's passage into cells.Examples of substituent groups that can replace one or more hydrogenatoms on a free amine and/or carboxylic acid moiety include, but are notlimited to, the following: aryl; steroids; carbohydrates (includingsugars); 1,2-diacylglycerol; alcohols; acyl (including lower acyl);alkyl (including lower alkyl); sulfonate ester (including alkyl orarylalkyl sulfonyl, such as methanesulfonyl and benzyl, wherein thephenyl group is optionally substituted with one or more substituents asprovided in the definition of an aryl given herein); optionallysubstituted arylsulfonyl; lipids (including phospholipids);phosphotidylcholine; phosphocholine; amino acid residues or derivatives;amino acid acyl residues or derivatives; peptides; cholesterols; orother pharmaceutically acceptable leaving groups which, whenadministered in vivo, provide the free amine. Any of these moieties canbe used in combination with the disclosed active agents to achieve adesired effect.

In some embodiments, compounds with one or more chiral centers areprovided. While racemic mixtures of compounds of the invention may beactive, selective, and bioavailable, isolated isomers may be of interestas well.

The compounds disclosed herein as active agents may contain chiralcenters, which may be either of the (R) or (S) configuration, or whichmay comprise a mixture thereof. Accordingly, the present invention alsoincludes stereoisomers of the compounds described herein, whereapplicable, either individually or admixed in any proportions.Stereoisomers may include, but are not limited to, enantiomers,diastereomers, racemic mixtures, and combinations thereof. Suchstereoisomers can be prepared and separated using conventionaltechniques, either by reacting enantiomeric starting materials, or byseparating isomers of compounds and prodrugs of the present invention.Isomers may include geometric isomers. Examples of geometric isomersinclude, but are not limited to, cis isomers or trans isomers across adouble bond. Other isomers are contemplated among the compounds of thepresent invention. The isomers may be used either in pure form or inadmixture with other isomers of the compounds described herein.

Various methods are known in the art for preparing optically activeforms and determining activity. Such methods include standard testsdescribed herein and other similar tests which are well known in theart. Examples of methods that can be used to obtain optical isomers ofthe compounds according to the present invention include the following:

i) physical separation of crystals whereby macroscopic crystals of theindividual enantiomers are manually separated. This technique mayparticularly be used when crystals of the separate enantiomers exist(i.e., the material is a conglomerate), and the crystals are visuallydistinct;

ii) simultaneous crystallization whereby the individual enantiomers areseparately crystallized from a solution of the racemate, possible onlyif the latter is a conglomerate in the solid state;

iii) enzymatic resolutions whereby partial or complete separation of aracemate by virtue of differing rates of reaction for the enantiomerswith an enzyme;

iv) enzymatic asymmetric synthesis, a synthetic technique whereby atleast one step of the synthesis uses an enzymatic reaction to obtain anenantiomerically pure or enriched synthetic precursor of the desiredenantiomer;

v) chemical asymmetric synthesis whereby the desired enantiomer issynthesized from an achiral precursor under conditions that produceasymmetry (i.e., chirality) in the product, which may be achieved usingchiral catalysts or chiral auxiliaries;

vi) diastereomer separations whereby a racemic compound is reacted withan enantiomerically pure reagent (the chiral auxiliary) that convertsthe individual enantiomers to diastereomers. The resulting diastereomersare then separated by chromatography or crystallization by virtue oftheir now more distinct structural differences and the chiral auxiliarylater removed to obtain the desired enantiomer;

vii) first- and second-order asymmetric transformations wherebydiastereomers from the racemate equilibrate to yield a preponderance insolution of the diastereomer from the desired enantiomer or wherepreferential crystallization of the diastereomer from the desiredenantiomer perturbs the equilibrium such that eventually in principleall the material is converted to the crystalline diastereomer from thedesired enantiomer. The desired enantiomer is then released from thediastereomers;

viii) kinetic resolutions comprising partial or complete resolution of aracemate (or of a further resolution of a partially resolved compound)by virtue of unequal reaction rates of the enantiomers with a chiral,non-racemic reagent or catalyst under kinetic conditions;

ix) enantiospecific synthesis from non-racemic precursors whereby thedesired enantiomer is obtained from non-chiral starting materials andwhere the stereochemical integrity is not or is only minimallycompromised over the course of the synthesis;

x) chiral liquid chromatography whereby the enantiomers of a racemateare separated in a liquid mobile phase by virtue of their differinginteractions with a stationary phase. The stationary phase can be madeof chiral material or the mobile phase can contain an additional chiralmaterial to provoke the differing interactions;

xi) chiral gas chromatography whereby the racemate is volatilized andenantiomers are separated by virtue of their differing interactions inthe gaseous mobile phase with a column containing a fixed non-racemicchiral adsorbent phase;

xii) extraction with chiral solvents whereby the enantiomers areseparated by virtue of preferential dissolution of one enantiomer into aparticular chiral solvent; and

xiii) transport across chiral membranes whereby a racemate is placed incontact with a thin membrane barrier. The barrier typically separatestwo miscible fluids, one containing the racemate, and a driving forcesuch as concentration or pressure differential causes preferentialtransport across the membrane barrier. Separation occurs as a result ofthe non-racemic chiral nature of the membrane which allows only oneenantiomer of the racemate to pass through.

The compound optionally may be provided in a composition that isenantiomerically enriched, such as a mixture of enantiomers in which oneenantiomer is present in excess, in particular, to the extent of 95% ormore, 96% or more, 97% or more, 98% or more, or 99% or more, including100%.

The terms (R), (S), (R,R), (S,S), (R,S) and (S,R) as used herein meanthat the composition contains a greater proportion of the named isomerof the compound in relation to other isomers. In a preferred embodiment,these terms indicate that the composition contains at least 90% byweight of the named isomer and 10% by weight or less of the one or moreother isomers; or more preferably about 95% by weight of the namedisomer and 5% or less of the one or more other isomers. In someembodiments, the composition may contain at least 99% by weight of thenamed isomer and 1% or less by weight of the one or more other isomers,or may contain 100% by weight of the named isomer and 0% by weight ofthe one of more other isomers. These percentages are based on the totalamount of the compound of the present invention present in thecomposition.

The compounds of the present invention may be utilized per se or in theform of a pharmaceutically acceptable ester, amide, salt, solvate,prodrug, or isomer. For example, the compound may be provided as apharmaceutically acceptable salt. If used, a salt of the drug compoundshould be both pharmacologically and pharmaceutically acceptable, butnon-pharmaceutically acceptable salts may conveniently be used toprepare the free active compound or pharmaceutically acceptable saltsthereof and are not excluded from the scope of this invention. Suchpharmacologically and pharmaceutically acceptable salts can be preparedby reaction of the drug with an organic or inorganic acid, usingstandard methods detailed in the literature.

Examples of pharmaceutically acceptable salts of the compounds usefulaccording to the invention include acid addition salts. Salts ofnon-pharmaceutically acceptable acids, however, may be useful, forexample, in the preparation and purification of the compounds. Suitableacid addition salts according to the present invention include organicand inorganic acids. Preferred salts include those formed fromhydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric,lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic,methanesulfonic, ethanesulfonic, p-toluenesulfonic, benzenesulfonic, andisethionic acids. Other useful acid addition salts include propionicacid, glycolic acid, oxalic acid, malic acid, malonic acid, benzoicacid, cinnamic acid, mandelic acid, salicylic acid, and the like.Particular example of pharmaceutically acceptable salts include, but arenot limited to, sulfates, pyrosulfates, bisulfates, sulfites,bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates,metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates,propionates, decanoates, caprylates, acrylates, formates, isobutyrates,caproates, heptanoates, propiolates, oxalates, malonates, succinates,suberates, sebacates, fumarates, maleates, butyne-1,4-dioates,hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates,dinitrobenzoates, hydroxybenzoates, methoxyenzoates, phthalates,sulfonates, xylenesulfonates, phenylacetates, phenylpropionates,phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates,tartrates, methanesulfonates, propanesulfonates,naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

An acid addition salt may be reconverted to the free base by treatmentwith a suitable base. Preparation of basic salts of acid moieties whichmay be present on a compound or prodrug useful according to the presentinvention may be prepared in a similar manner using a pharmaceuticallyacceptable base, such as sodium hydroxide, potassium hydroxide, ammoniumhydroxide, calcium hydroxide, triethylamine, or the like.

Esters of the active agent compounds according to the present inventionmay be prepared through functionalization of hydroxyl and/or carboxylgroups that may be present within the molecular structure of thecompound. Amides and prodrugs may also be prepared using techniquesknown to those skilled in the art. For example, amides may be preparedfrom esters, using suitable amine reactants, or they may be preparedfrom an anhydride or an acid chloride by reaction with ammonia or alower alkyl amine Moreover, esters and amides of compounds of theinvention can be made by reaction with a carbonylating agent (e.g.,ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoylchloride, methyl isocyanate, ethyl chloroformate, methanesulfonylchloride) and a suitable base (e.g., 4-dimethylaminopyridine, pyridine,triethylamine, potassium carbonate) in a suitable organic solvent (e.g.,tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) ata temperature of 0° C. to 60° C. Prodrugs are typically prepared bycovalent attachment of a moiety, which results in a compound that istherapeutically inactive until modified by an individual's metabolicsystem. Examples of pharmaceutically acceptable solvates include, butare not limited to, compounds according to the invention in combinationwith water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, aceticacid, or ethanolamine.

In the case of solid compositions, it is understood that the compoundsused in the methods of the invention may exist in different forms. Forexample, the compounds may exist in stable and metastable crystallineforms and isotropic and amorphous forms, all of which are intended to bewithin the scope of the present invention.

If a compound useful as an active agent according to the invention is abase, the desired salt may be prepared by any suitable method known tothe art, including treatment of the free base with an inorganic acid,such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid and the like, or with an organic acid, such as aceticacid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonicacid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid,pyranosidyl acids such as glucuronic acid and galacturonic acid,alpha-hydroxy acids such as citric acid and tartaric acid, amino acidssuch as aspartic acid and glutamic acid, aromatic acids such as benzoicacid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid orethanesulfonic acid, or the like.

If a compound described herein as an active agent is an acid, thedesired salt may be prepared by any suitable method known to the art,including treatment of the free acid with an inorganic or organic base,such as an amine (primary, secondary or tertiary), an alkali metal oralkaline earth metal hydroxide or the like. Illustrative examples ofsuitable salts include organic salts derived from amino acids such asglycine and arginine, ammonia, primary, secondary and tertiary amines,and cyclic amines such as piperidine, morpholine and piperazine, andinorganic salts derived from sodium, calcium, potassium, magnesium,manganese, iron, copper, zinc, aluminum and lithium.

Some representative, non-limiting compounds of the present inventioninclude the following 4-pyridine-substituted epibatidine compoundsaccording to Formula Ia.

TABLE 1 Representative compounds of Formula Ia

X R₂ H H H F H Cl H Br H NH₂ H N(CH₃)H H N(CH₃)₂ H N(CH₂CH₃)H HN(CH₂CH₃)₂ H CH₃O H CH₃CH₂O H CH₃CH₂CH₂O H CH₃SO₂ H CF₃SO₂ H CN H H₂NSO₂F H F F F Cl F Br F NH₂ F N(CH₃)H F N(CH₃)₂ F N(CH₂CH₃)H F N(CH₂CH₃)₂ FCH₃O F CH₃CH₂O F CH₃CH₂CH₂O F CH₃SO₂ F CF₃SO₂ F CN F H₂NSO₂

Other representative, non-limiting compounds of the present inventioninclude the following 3-pyridine-substituted epibatidine compoundsaccording to Formula Ib.

TABLE 2 Representative compounds of Formula Ib

X R₂ H H H F H Cl H Br H NH₂ H N(CH₃)H H N(CH₃)₂ H N(CH₂CH₃)H HN(CH₂CH₃)₂ H CH₃O H CH₃CH₂O H CH₃CH₂CH₂O H CH₃SO₂ H CF₃SO₂ H CN H H₂NSO₂F H F F F Cl F Br F NH₂ F N(CH₃)H F N(CH₃)₂ F N(CH₂CH₃)H F N(CH₂CH₃)₂ FCH₃O F CH₃CH₂O F CH₃CH₂CH₂O F CH₃SO₂ F CF₃SO₂ F CN F H₂NSO₂

Further representative, non-limiting compounds of the present inventioninclude the following 2-thiophene-substituted epibatidine compoundsaccording to Formula Ic.

TABLE 3 Representative compounds of Formula Ic

X R₂ H H H F H Cl H Br H NH₂ H N(CH₃)H H N(CH₃)₂ H N(CH₂CH₃)H HN(CH₂CH₃)₂ H CH₃O H CH₃CH₂O H CH₃CH₂CH₂O H CH₃SO₂ H CF₃SO₂ H CN H H₂NSO₂F H F F F Cl F Br F NH₂ F N(CH₃)H F N(CH₃)₂ F N(CH₂CH₃)H F N(CH₂CH₃)₂ FCH₃O F CH₃CH₂O F CH₃CH₂CH₂O F CH₃SO₂ F CF₃SO₂ F CN F H₂NSO₂

Further representative, non-limiting compounds of the present inventioninclude the following 2-thiophene-substituted epibatidine compoundsaccording to Formula Ic.

TABLE 4 Representative compounds of Formula Ic

X R₂ H H H F H Cl H Br H NH₂ H N(CH₃)H H N(CH₃)₂ H N(CH₂CH₃)H HN(CH₂CH₃)₂ H CH₃O H CH₃CH₂O H CH₃CH₂CH₂O H CH₃SO₂ H CF₃SO₂ H CN H H₂NSO₂F H F F F Cl F Br F NH₂ F N(CH₃)H F N(CH₃)₂ F N(CH₂CH₃)H F N(CH₂CH₃)₂ FCH₃O F CH₃CH₂O F CH₃CH₂CH₂O F CH₃SO₂ F CF₃SO₂ F CN F H₂NSO₂

Further representative, non-limiting compounds of the present inventioninclude the following 3-thiophene-substituted epibatidine compoundsaccording to Formula Id.

TABLE 5 Representative compounds of Formula Id

X R₂ H H H F H Cl H Br H NH₂ H N(CH₃)H H N(CH₃)₂ H N(CH₂CH₃)H HN(CH₂CH₃)₂ H CH₃O H CH₃CH₂O H CH₃CH₂CH₂O H CH₃SO₂ H CF₃SO₂ H CN H H₂NSO₂F H F F F Cl F Br F NH₂ F N(CH₃)H F N(CH₃)₂ F N(CH₂CH₃)H F N(CH₂CH₃)₂ FCH₃O F CH₃CH₂O F CH₃CH₂CH₂O F CH₃SO₂ F CF₃SO₂ F CN F H₂NSO₂

The compounds of the present invention may display different types ofbiological activities. In some embodiments, the compounds of the presentinvention may be capable of acting as agonists and/or antagonists of oneor more nicotinic acetylcholine receptors. For example, in someembodiments, the compounds may function as agonists by binding tonAChRs. For example, in other embodiments, the compounds may function asantagonists by binding either to the active site or to an alternativesite on the receptor, inhibiting the ability of agonists (e.g.,nicotine) to interact with the receptor. In certain embodiments, thecompounds of the present invention may show enhanced selectivity for oneor more types of nicotinic receptor. In some embodiments, the compoundsmay be selective for α₄β₂ nAChRs. In certain specific embodiments, somecompounds of the invention may act as noncompetitive functionalantagonists at the α₄β₂ nAChRs.

Methods of Preparation

The present invention also encompasses methods of preparing compoundswith structures encompassed by Formula I, including but not limited tocompounds with structures according to Formulae Ia, Ib, Ic, and Id.Representative synthetic procedures for preparing compounds of thepresent invention are provided in Schemes 1-18 in the Experimentalsection. One of skill in the art would be able to adapt these methods asrequired to accommodate various functional groups that may affect thechemistry of the synthesis.

Compositions

While it is possible for the compounds of the present invention to beadministered in the raw chemical form, it is preferred for the compoundsto be delivered as a pharmaceutical formulation. Accordingly, there areprovided by the present invention pharmaceutical compositions comprisingat least one compound capable of acting as an agonist or antagonist ofthe nicotinic receptors. As such, the formulations of the presentinvention comprise a compound of any of the formulas noted herein, asdescribed above, or a pharmaceutically acceptable ester, amide, salt, orsolvate thereof, together with one or more pharmaceutically acceptablecarriers therefor, and optionally, other therapeutic ingredients.

By “pharmaceutically acceptable carrier” is intended a carrier,adjuvant, accessory, or excipient that is conventionally used in the artto facilitate the storage, administration, and/or the healing effect ofthe agent. The carrier(s) must be pharmaceutically acceptable in thesense of being compatible with the other ingredients of the formulationand not unduly deleterious to the recipient thereof. A carrier may alsoreduce any undesirable side effects of the agent. Such carriers areknown in the art. See, Wang et al. (1980) J. Parent. Drug Assn.34(6):452-462, herein incorporated by reference in its entirety.

Adjuvants or accessory ingredients for use in the formulations of thepresent invention can include any pharmaceutical ingredient commonlydeemed acceptable in the art, such as fillers, stabilizers, diluents,buffers, binders, disintegrants, thickeners, lubricants, preservatives(including antioxidants), flavoring and coloring agents, taste-maskingagents, inorganic salts (e.g., sodium chloride), antimicrobial agents(e.g., benzalkonium chloride), sweeteners, antistatic agents,surfactants (e.g., polysorbates such as “TWEEN 20” and “TWEEN 80”, andpluronics such as F68 and F88, available from BASF), sorbitan esters,lipids (e.g., phospholipids such as lecithin and otherphosphatidylcholines, phosphatidylethanolamines, fatty acids and fattyesters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA,zinc and other such suitable cations). Exemplary excipients includewater, saline, dextrose, glycerol, ethanol, and combinations thereof.Other exemplary pharmaceutical excipients and/or additives suitable foruse in the compositions according to the invention are listed inRemington: The Science & Practice of Pharmacy, 21^(st) ed., LippincottWilliams & Wilkins (2006); in the Physician's Desk Reference, 64^(th)ed., Thomson PDR (2010); and in Handbook of Pharmaceutical Excipients,6^(th) ed., Eds. Raymond C. Rowe et al., Pharmaceutical Press (2009),which are incorporated herein by reference.

Binders are generally used to facilitate cohesiveness of the tablet andensure the tablet remains intact after compression. Suitable bindersinclude, but are not limited to: starch, polysaccharides, gelatin,polyethylene glycol, propylene glycol, waxes, and natural and syntheticgums. Acceptable fillers include silicon dioxide, titanium dioxide,alumina, talc, kaolin, powdered cellulose, and microcrystallinecellulose, as well as soluble materials, such as mannitol, urea,sucrose, lactose, dextrose, sodium chloride, and sorbitol. Lubricantsare useful for facilitating tablet manufacture and include vegetableoils, glycerin, magnesium stearate, calcium stearate, and stearic acid.Disintegrants, which are useful for facilitating disintegration of thetablet, generally include starches, clays, celluoses, algins, gums, andcrosslinked polymers. Diluents, which are generally included to providebulk to the tablet, may include dicalcium phosphate, calcium sulfate,lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, andpowdered sugar. Surfactants suitable for use in the formulationaccording to the present invention may be anionic, cationic, amphoteric,or nonionic surface active agents. Stabilizers may be included in theformulations to inhibit or lessen reactions leading to decomposition ofthe active agent, such as oxidative reactions.

Formulations of the present invention may include short-term,rapid-onset, rapid-offset, controlled release, sustained release,delayed release, and pulsatile release formulations, providing theformulations achieve administration of a compound as described herein.See Remington's Pharmaceutical Sciences (18^(th) ed.; Mack PublishingCompany, Eaton, Pa., 1990), herein incorporated by reference in itsentirety.

Pharmaceutical formulations according to the present invention aresuitable for various modes of delivery, including oral, parenteral(including intravenous, intramuscular, subcutaneous, intradermal, andtransdermal), topical (including dermal, buccal, and sublingual), andrectal administration. The most useful and/or beneficial mode ofadministration can vary, especially depending upon the condition of therecipient and the disorder being treated. However, in preferredembodiments, the formulation is for oral delivery, as oraladministration may provide the drug while maintaining abuse resistance.

The pharmaceutical formulations may be conveniently made available in aunit dosage form, whereby such formulations may be prepared by any ofthe methods generally known in the pharmaceutical arts. Generallyspeaking, such methods of preparation comprise combining (by variousmethods) an active agent, such as the compounds of Formula I accordingto the present invention (or a pharmaceutically acceptable ester, amide,salt, or solvate thereof), with a suitable carrier or other adjuvant,which may consist of one or more ingredients. The combination of theactive ingredient with the one or more adjuvants is then physicallytreated to present the formulation in a suitable form for delivery(e.g., shaping into a tablet or forming an aqueous suspension).

Pharmaceutical formulations according to the present invention suitableas oral dosage may take various forms, such as tablets, capsules,caplets, and wafers (including rapidly dissolving or effervescing), eachcontaining a predetermined amount of the active agent. The formulationsmay also be in the foul). of a powder or granules, a solution orsuspension in an aqueous or non-aqueous liquid, and as a liquid emulsion(oil-in-water and water-in-oil). The active agent may also be deliveredas a bolus, electuary, or paste. It is generally understood that methodsof preparations of the above dosage forms are generally known in theart, and any such method would be suitable for the preparation of therespective dosage forms for use in delivery of the compounds accordingto the present invention. Solid formulations of the invention, whenparticulate, will typically comprise particles with sizes ranging fromabout 1 nanometer to about 500 microns. In general, for solidformulations intended for intravenous administration, particles willtypically range from about 1 nm to about 10 microns in diameter.

A tablet containing a compound according to the present invention may bemanufactured by any standard process readily known to one of skill inthe art, such as, for example, by compression or molding, optionallywith one or more adjuvant or accessory ingredient. The tablets mayoptionally be coated or scored and may be formulated so as to provideslow or controlled release of the active agent.

Solid dosage forms may be formulated so as to provide a delayed releaseof the active agent, such as by application of a coating. Delayedrelease coatings are known in the art, and dosage forms containing suchmay be prepared by any known suitable method. Such methods generallyinclude that, after preparation of the solid dosage form (e.g., a tabletor caplet), a delayed release coating composition is applied.Application can be by methods such as airless spraying, fluidized bedcoating, use of a coating pan, or the like. Materials for use as adelayed release coating can be polymeric in nature, such as cellulosicmaterial (e.g., cellulose butyrate phthalate, hydroxypropylmethylcellulose phthalate, and carboxymethyl ethylcellulose), andpolymers and copolymers of acrylic acid, methacrylic acid, and estersthereof.

Solid dosage forms according to the present invention may also besustained release (i.e., releasing the active agent over a prolongedperiod of time), and may or may not also be delayed release. Sustainedrelease formulations are known in the art and are generally prepared bydispersing a drug within a matrix of a gradually degradable orhydrolyzable material, such as an insoluble plastic, a hydrophilicpolymer, or a fatty compound. Alternatively, a solid dosage form may becoated with such a material.

Formulations for parenteral administration include aqueous andnon-aqueous sterile injection solutions, which may further containadditional agents, such as anti-oxidants, buffers, bacteriostats, andsolutes, which render the fatinulations isotonic with the blood of theintended recipient. The formulations may include aqueous and non-aqueoussterile suspensions, which contain suspending agents and thickeningagents. Such formulations for parenteral administration may be presentedin unit-dose or multi-dose containers, such as, for example, sealedampoules and vials, and may be stores in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample, water (for injection), immediately prior to use. Extemporaneousinjection solutions and suspensions may be prepared from sterilepowders, granules, and tablets of the kind previously described.

The compounds according to the present invention may also beadministered transdermally, wherein the active agent is incorporatedinto a laminated structure (generally referred to as a “patch”) that isadapted to remain in intimate contact with the epidermis of therecipient for a prolonged period of time. Typically, such patches areavailable as single layer “drug-in-adhesive” patches or as multi-layerpatches where the active agent is contained in a layer separate from theadhesive layer. Both types of patches also generally contain a backinglayer and a liner that is removed prior to attachment to the skin of therecipient. Transdermal drug delivery patches may also be comprised of areservoir underlying the backing layer that is separated from the skinof the recipient by a semi-permeable membrane and adhesive layer.Transdermal drug delivery may occur through passive diffusion or may befacilitated using electrotransport or iontophoresis.

Formulations for rectal delivery of the compounds of the presentinvention include rectal suppositories, creams, ointments, and liquids.Suppositories may be presented as the active agent in combination with acarrier generally known in the art, such as polyethylene glycol. Suchdosage forms may be designed to disintegrate rapidly or over an extendedperiod of time, and the time to complete disintegration can range from ashort time, such as about 10 minutes, to an extended period of time,such as about 6 hours.

The amount of the compound of any one of the formulas disclosed hereincontained in the formulation will vary depending the specific compoundor prodrug selected, dosage form, target patient population, and otherconsiderations, and will be readily determined by one skilled in theart. The amount of the compound in the formulation will be that amountnecessary to deliver a therapeutically effective amount of the compoundto a patient in need thereof to achieve at least one of the therapeuticeffects associated with the compounds of the invention. In practice,this will vary widely depending upon the particular compound, itsactivity, the severity of the condition to be treated, the patientpopulation, the stability of the formulation, and the like. Compositionswill generally contain anywhere from about 1% by weight to about 99% byweight of a compound of the invention, typically from about 5% to about70% by weight, and more typically from about 10% to about 50% by weight,and will also depend upon the relative amounts of excipients/additivescontained in the composition.

Combinations

In specific embodiments, active agents used in combination withcompounds of the present invention comprise one or more compoundsgenerally recognized as useful for treating the conditions discussedherein. In one embodiment, the use of two or more drugs, which may be ofdifferent therapeutic classes, may enhance efficacy and/or reduceadverse effects associated with one or more of the drugs.

For example, in certain embodiments, the present invention providescompositions for treating nicotine dependence, comprising a combinationof a compound of the present invention and one or more known nicotinedependence drugs. For example, a compound of the present invention maybe used in combination with bupropion and/or varenicline. The compoundsdisclosed herein may also be used in combination with one or more typeof nicotinic replacement therapy (NRT). For example, in certainembodiments, the compounds of the present invention may be used incombination with a nicotine patch, nicotine inhaler, nasal spray, gum,sublingual tablet, and/or lozenge).

In certain embodiments, a compound of Formula I may also be combinedwith one or more nicotinic drugs. One particular class of nicotinicdrugs that may be used with compounds of the present inventionencompasses α4-β2 nicotinic receptor partial agonists, includingvarenicline (CHANTIX®). Another nicotinic drug approved for thetreatment of nicotine dependence, bupropion (ZYBAN®), which is an α3-β4nicotinic receptor antagonist, may be combined with any of the compoundsprovided herein.

In some embodiments, other compounds that have demonstrated off-labelsuccess for smoking cessation may be combined with compounds of FormulaI. Other drug therapies that may be prescribed and used in nicotinedependence in combination with the compounds of the present inventioninclude nortriptyline and doxepin, both tricyclic antidepressants.Additionally, fluoxetine (PROZAC®) and buspirone (BUSPAR®) have beenused to treat nicotine addiction. Clonidine, an α2-noradrenergic agonistused to treat hypertension, has also shown beneficial effects innicotine addiction and studies suggest that mecamylamine may also aid intreatment for nicotine addiction. Immunotherapy may also be used inconjunction with compounds of the present invention, as recent studieshave demonstrated a prototype vaccine against nicotine that may inducethe production of antibodies that bind nicotine in the blood, preventingit from reaching the nicotine receptors.

In some embodiments, compounds of the present invention are used inconjunction with behavioral treatment. For example, psychologicaltreatment (including, but not limited to, psychological counseling,group therapy, and/or behavior therapy), skills training to deal withhigh-risk situations as well as an exercise regimen may prove effectiveat treating nicotine dependence when used in combination with treatmentusing a compound of the present invention.

Combinations of compounds of the present invention with othertherapeutic agents are also included in the present invention, whereinthe condition to be treated is responsive to a change in the activationof the nicotinic acetylcholine receptors. For example, it may relate totreatment of Alzheimer's disease, Parkinson's disease, pain (analgesicactivity), depression, Tourette's syndrome, inflammatory bowel syndrome,schizophrenia, anxiety, epilepsy, attention-deficit hyperactivitydisorder, ulcerative colitis and obesity. Accordingly, the presentinvention also provides compositions for treating these conditions thatmay comprise a combination of a compound of the present invention andone or more additional compounds. All combinations of compounds or drugsof the present invention with other therapeutic agents are included inthe present invention, wherein the condition to be treated is anycondition that may be responsive to modulation of activation ofnicotinic receptors.

For example, in some embodiments, the present invention provides amethod and compositions for treating depression, comprisingadministering a combination of a compound of the present invention andone or more known antidepressants. Antidepressants useful according tothe invention comprise selective serotonin reuptake inhibitors (SSRIs),tricyclics, serotonin norepinephrine reuptake inhibitors (5-HT-NE dualreuptake inhibitors), and norepinephrine and dopamine reuptakeinhibitors (NDRIs).

In one embodiment, compounds or prodrugs of the present invention may becombined with one or more compounds that are serotonin reuptakeinhibitors. Serotonin reuptake inhibitors increase the extracellularlevel of the serotonin by inhibiting its reuptake into the presynapticcell, which increases the level of serotonin available to bind to andstimulate the postsynaptic receptor. Examples of SSRIs includefluoxetine (PROZAC®) paroxetine (PAXIL®), sertraline (ZOLOFT®),citalopram (CELEXA®), escitalopram (LEXAPRO®), nefazodone (SERZONE®) andfluvoxamine (LUVOX®).

In another embodiment, compounds of the present invention may becombined with one or more compounds that at least partially inhibit thefunction of monoamine oxidase. Monoamine oxidase inhibitors (MAOIs)comprise a class of compounds understood to act by inhibiting theactivity of monoamine oxidase, an enzyme generally found in the brainand liver of the human body, which functions to break down monoaminecompounds, typically through deamination. There are two isoforms ofmonoamine oxidase inhibitors, MAO-A and MAO-B. The MAO-A isoformpreferentially deaminates monoamines typically occurring asneurotransmitters (e.g., serotonin, melatonin, epinephrine,norepinephrine, and dopamine). Thus, MAOIs have been historicallyprescribed as antidepressants and for treatment of other socialdisorders, such as agoraphobia and social anxiety. The MAO-B isoformpreferentially deaminates phenylethylamine and trace amines. Dopamine isequally deaminated by both isoforms. MAOIs may by reversible ornon-reversible and may be selective for a specific isoform. For example,the MAOI moclobemide (also known as Manerix or Aurorix) is known to beapproximately three times more selective for MAO-A than MAO-B. Anycompound generally recognized as being an MAOI may be useful accordingto the present invention. Non-limiting examples of MAOIs useful incombination with compounds of the present invention for preparingcompositions according to the invention include the following:isocarboxazid (MARPLAN®); moclobemide (Aurorix, Manerix, or Moclodura);phenelzine (NARDIL®); tranylcypromine (PARNATE®); selegiline (ELDEPRYL®,EMSAM®, or 1-deprenyl); lazabemide; nialamide; iproniazid (marsilid,iprozid, ipronid, rivivol, or propilniazida); iproclozide; toloxatone;harmala; brofaromine (Consonar); benmoxin (Neuralex); and certaintryptamines, such as 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) or5-MeO-AMT (5-methoxy-α-methyltryptamine).

According to still another embodiment of the invention, compounds of anyone of the formulas disclosed herein may be combined with one or morecompounds that is a norepinephrine reuptake inhibitor (NRI). NRIs arealso known as noradrenaline reuptake inhibitors (NARIs) and generallyfunction to elevate the level of norepinephrine in the central nervoussystem (CNS) by inhibiting reuptake of norepinephrine from the synapticcleft into the presynaptic neuronal terminal. Norepinephrine is acatecholamine and phenylethylamine that functions as a neurotransmitterand is known to affect many conditions. Any compound typicallyrecognized as inhibiting the reuptake of norepinephrine in the CNS canbe used according to the present invention. Non-limiting examples ofNRIs useful according to the invention comprise atomoxetine(STRATTERA®), reboxetine (EDRONAX®, VESTRA®, or NOREBOX®), viloxazine(EMOVIT®, VIVALAN®, VIVARINT®, or VIVILAN®), maprotiline (DEPRILEPT®,LUDIOMIL®, or PSYMION®), bupropion (WELLBUTRIN® or ZYBAN®), andradafaxine.

Further non-limiting examples of specific antidepressants usefulaccording to the invention include tricyclics such as amitriptyline,nortriptyline, and desipramine; serotonin-norepinephrine reuptakeinhibitors such as venlafaxine (EFFEXOR®), duloxetine (CYMBALTA®), andmilnacipran; tetracyclics such as maprotiline and mirtazapine; and otherclasses of compounds, including triazolopyridines such as trazodone.

The above compounds and classes of compounds are only examples of thetypes of active agents that can be used in combination with a compoundof the present invention for the treatment of mood disorders, sleepdisorders, or attention deficit disorders and are not intended to belimiting of the invention. Rather, various further active agents can becombined with one or more compounds of the present invention accordingto the invention. For example, any drug generally recognized as being anantidepressant, antinarcoleptic, or ADHD treatment can be used incombination with one or more compounds of the present invention.Moreover, it is possible according to the invention to combine two ormore additional active agents with a compound of the present inventionfor the treatment of the noted conditions.

Non-limiting examples of further active agents that can be combined withcompounds of the present invention include: mood stabilizers (such aslithium, olanzipine, verapamil, quetiapine, lamotrigine, carbamazepine,valproate, oxcarbazepine, risperidone, aripiprazole, and ziprasidone);antipsychotics (such as haloperidol and other butyrophenones,chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and otherphenothiazines, and clozapine); serotonin receptor antagonist (5-HT2 and5-HT3 antagonists) (such as ondansetron, tropisetron, katenserin,methysergide, cyproheptadine, and pizotifen); serotonin receptoragonists (5-HT1A receptor agonists) (such as buspirone); stimulants[such as caffeine, ADDERALL®, methylphenidate (METADATE®, RITALIN®, orCONCERTA®), pemoline (CYLERT®), or modafinil (PROVIGIL®)]; andgamma-hydroxybutyrate (GHB) (XYREM®). Although the above compounds aredescribed in terms of classes of compounds and specific compounds, it isunderstood that there is substantial overlap between certain classes ofcompounds (such as between mood stabilizers, antipsychotics,antidepressants, and serotonin receptor antagonists). Thus, specificcompounds exemplifying a specific class of compounds may also properlybe identified with one or more further classes of compounds.Accordingly, the above classifications should not be viewed as limitingthe scope of the types of compounds useful in combination with compoundsof the present invention for treating the conditions described herein.

The compounds of any of the formulas disclosed herein and the optionalone or more other therapeutic agents may be contained within a singlecomposition or alternatively may be administered concurrently orsequentially (consecutively) in any order. For sequentialadministration, each of the compound of the formulas disclosed hereinand the one or more other therapeutic agents can be formulated in itsown pharmaceutical composition, each of which is to be administeredsequentially, in any order. Alternatively, the compound of the formulasdisclosed herein and the one or more other therapeutic agents can beformulated together. The compositions may be formulated for oral,systemic, topical, intravenous, intraparenteral, intravaginal,intraocular, transbuccal, transmucosal, or transdermal administration.

Methods of Use

In a further embodiment, the present invention provides a method forpreventing, treating, or delaying the progression of disorders that arealleviated by the modulation of activation of the nAChRs of a patient,the method comprising administering a therapeutically effective amountof at least one compound of the formulas disclosed herein to thepatient. In certain embodiments, administration of the compound resultsin the formation of one or more active metabolites.

In particular, the present invention relates to the field of treatingnicotine dependence in animals, particularly humans and other mammals,and associated effects of these conditions. Dependence has its commonmeaning, e.g., the condition that exists when an individual persists inthe use of a substance despite impairment or distress related to the useof the substance. While not wishing to be bound by theory, it isbelieved that by nicotine dependence may be successfully treated byblocking some of the pharmacological effects of nicotine, while alsodissociating some of the reinforcing effects of nicotine. As usedherein, a patient in need of treatment for nicotine dependence is aperson who uses nicotine-containing products on a regular basis and iseither unable or unwilling to terminate this use. In certain embodimentsof the present invention, the method relates to administration of acompound disclosed herein, concurrent with or in advance of the use ofnicotine. Accordingly, the patient addicted to nicotine would also besubject to the effects of the compounds while using the nicotineproduct, which can be beneficial in dissociating the reinforcing effectsof smoking from the act of nicotine use itself

In certain embodiments, the present invention is directed to a method ofpreventing nicotine dependence, by administering a compound of thepresent invention. A person in need of preventing nicotine dependencemay be a non-user of nicotine products or an occasional user, who isconcerned about the possibility of developing a dependence on nicotineproducts. The method of preventing nicotine dependence may be practicedby administering a compound of the present invention prophylactically,preferably in advance of the act of using a nicotine product. In thisfashion, the patient will not develop a strong association of the act ofsmoking with the reinforcing effects of smoking The present inventionmay further relate to a method of preventing nicotine dependence byadministering a compound of the present invention to a person who is inthe process of controlling his/her nicotine dependence in order toprevent a relapse.

In some embodiments, the invention may relate to the treatment of otherconditions that may benefit from modulation of nAChR activation. Forexample, it may relate to treatment of Alzheimer's disease, Parkinson'sdisease, pain (analgesic activity), depression, Tourette's syndrome,inflammatory bowel syndrome, schizophrenia, anxiety, epilepsy,attention-deficit hyperactivity disorder, ulcerative colitis andobesity. For example, the compounds of the present invention may also beapplicable to treating depression and depressive conditions in animals,particularly humans and other mammals, and associated effects of theseconditions. Depression has its common meaning, e.g., a common mentaldisorder that presents with depressed mood, loss of interest orpleasure, feelings of guilt or low self-worth, disturbed sleep orappetite, low energy, and poor concentration or a mental statecharacterized by a pessimistic sense of inadequacy and a despondent lackof activity. Physical changes, such as insomnia, anorexia, weight loss,and decreased energy and libido can also occur as a result ofdepression. Depression includes dysthymic disorder or dysthymia, definedas a chronic low-grade depression and major depression as well as otherstages or levels of depression. It also includes post-partum depression.

The method of treatment generally includes administering atherapeutically effective amount of a compound of a formula disclosedherein, optionally in a pharmaceutical composition including one or morepharmaceutically acceptable carriers. The therapeutically effectiveamount is preferably sufficient to interact with and cause a change inthe level of activation one or more nAChRs (i.e., to cause activation ofthe receptor (agonist) or to deactivate the receptor (antagonist)). Thetherapeutically effective amount is further preferably sufficient tocause some relief to the patient in the symptoms of the disorder forwhich the patient is being treated.

For example, in one embodiment, a method of treating nicotine dependenceis provided. In such methods, a therapeutically effective amount of acompound of the present invention to treat a patient with nicotineaddiction may be that amount capable of exerting some effect on thenicotinic receptors. In another embodiment, a method of treatingdepression is provided. A therapeutically effective amount of a compoundor prodrug of the present invention to treat a patient with depressionmay be that amount capable of providing some relief from symptoms suchas changes in mood, feelings of intense sadness and despair, mentalslowing, loss of concentration, pessimistic worry, agitation, andself-deprecation and/or from physical changes such as insomnia, anorexiaand weight loss, and decreased energy and libido.

The therapeutically effective dosage amount of any specific formulationwill vary somewhat from drug to drug, patient to patient, and willdepend upon factors such as the condition of the patient and the routeof delivery. It may further be dependent on the presence of otheragonists and antagonists present in the subject's system and on thedegree of binding or inhibition of binding desired. When administeredconjointly with other pharmaceutically active agents, even less of thecompound of the invention may be therapeutically effective. Furthermore,the therapeutically effective amount may vary depending on the specificcondition to be treated. Precise amounts of active ingredient requiredto be administered depend on the judgment of the practitioner and arepeculiar to each individual. However, suitable dosages may range fromabout 0.01 to about 1,000, preferably about 0.25 to about 500, and morepreferably 10 to 50 milligrams of active ingredient per kilogram bodyweight of individual per day and depend on the route of administration.For oral administration, 1 to 100 milligrams of active ingredient perkilogram body weight of individual per day is a preferred dose. However,the exact dosage must be determined by factoring in certain variables,including but not limited to, the rate of degradation in the stomach,absorption from the stomach, and other medications administered.

Possible routes of delivery include buccally, subcutaneously,transdermally, intramuscularly, intravenously, orally, or by inhalation.The compounds of the invention can be administered once or byintermittent administration (e.g., once a day or several times a day).The daily dose can be administered either by a single dose in the formof an individual dosage unit or several smaller dosage units or bymultiple administration of subdivided dosages at certain intervals. Incertain embodiments, there may be an initial administration followed byrepeated doses at one or more hour intervals by a subsequent injectionor other administration. Alternatively, continuous intravenous infusionsufficient to maintain appropriate concentrations in the blood iscontemplated.

In certain other embodiments, appropriately labeled compound representedby Formula I may be useful in a variety of other applications. Forexample, the labeled compounds may be used for imaging drug andneurotransmitter receptors by PET or SPECT. The labeled compounds mayalso be useful in ligand binding assays. Since little is known about thein vivo disposition of nAChRs both before and after chronic nicotineexposure, such labeled compounds would be very useful in the study ofnAChRs. The labeled compounds of the present invention may be usefulradio-labeled ligands for imaging the nicotinic receptor in vivo by PETor SPECT.

For use in imaging and tracer applications, the compounds of the presentinvention may be labeled with any detectable label. Accordingly, thepresent invention includes compounds represented by Formula I which arelabeled with at least one labeling atom. Preferably, the label is aradioactive element. Examples of suitable radioactive elements include³H, ¹¹C, ¹⁴C, ³²P, ³⁵S, ¹⁸F, ³⁶Cl, ⁵¹Cr, ⁵⁷Co, ¹⁹Fe, 90Y, ¹²³I, ¹²⁵I,and ¹³¹I. Preferred radioactive elements include 3H, 11_(C,) ¹⁸F, and¹²³I. In certain embodiments, the labeled compound may be represented byFormula I in which one or more hydrogen atom in the formula is replacedwith ³H and/or one or more carbon atoms is replaced with ¹¹C and/or ¹⁴C.

EXAMPLES Example 1 Synthesis of Various Epibatidine Analogues

The synthetic route to the desired analogues commenced with preparationof the intermediate7-tert-butoxycarbonyl-2-(p-toylsulfonyl)-7-azabicyclo[2.2.1]hepta-2,5-diene,1, obtained via a Diels-Alder reaction between N-Boc pyrrole andp-toylsufonylacetylene. Scheme 1 below outlines a multi-gram reaction toprepare the monoolefin 4 in 3 steps starting from 70 grams of diene 1using a similar protocol as previously reported in earlier work (seeBrieaddy, L. E. et al., Tetrahedron Lett. 1998, 38, 5321-5322,incorporated herein by reference).

The route used in the synthesis of fumarate salts 12a-b and 13a-b isshown in Scheme 2. A Heck cross-coupling of olefin 4 with2-amino-5-iodopyridine (5) prepared according to a reported procedure(Giantsidis, J. et al., J. Coord. Chem., 2002, 55, 795-803, incorporatedherein by reference), provided intermediate 6 in a 60% yield uponheating at 100° C. for 3 days under conditions previously reported (seeCarroll, F. I. et al., J. Med. Chem., 2001, 44, 2229-2237, incorporatedherein by reference). Bromination of 6 was accomplished through the useof bromine in glacial acetic acid to provide the bromo derivative 7 in83% yield. The bromo intermediate 7 was subjected to Suzukicross-coupling reactions with the respective pyridinyl boronic acids inthe presence of Pd(OAc)₂ and P(o-tolyl)₃ as the catalytic system, Na₂CO₃as the base, DME as solvent, and a catalytic amount of water and washeated at 80° C. for 5 h to furnish the bipyridine derivatives 8a (seeGao, Y. et al., J. Med. Chem., 2007, 50, 3814-3824, incorporated hereinby reference), 8b, 9a and 9b in modest to good yields. Introduction ofthe fluorine and simultaneous removal of the BOC protecting group wereperformed through diazotization reactions using 70% HF in pyridine tofurnish the free base amine derivatives 10a, 10b, 11a and 11brespectively. Finally, the fumarate salts of the respective amines wereprepared and recrystallized from MeOH/ether to furnish the epibatidineanalogues as fumarate salts 12a, 12b, 13a, and 13b respectively.

Experimental Procedure:

Preparation of 2-amino-5-iodopyridine (5).

To a solution of 2-aminopyridine (10.2 g, 10.8 mol) in glacial aceticacid (65 mL) and water (13 mL), was added periodic acid (4.92 g, 21.6mol) and iodine (11.0 g, 43.2 mol). The mixture was treated with H₂SO₄(1.9 mL) dropwise and stirred at 80° C. for 4 h. The reaction mixturewas allowed to cool to room temperature and diluted with a saturatedaqueous solution of sodium thiosulfate. The solution was basified withNH₄OH to pH 8-9 and extracted with ether (3×50 mL). The combined organicextracts were dried over MgSO₄, filtered, and concentrated in vacuo. Theresidue was purified by flash chromatography through an ISCO column(SiO₂, ethyl acetate/hexanes, 20/80 to 40/60) to give the expected 5 (15g, 63%) as a yellow solid.

7-tert-Butoxycarbonyl-2-exo-(2′-amino-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane(6).

The azabicyclo intermediate 6 was prepared through a Heck cross-couplingreaction as reported (see Carroll, F. I. et al., J. Med. Chem., 2001,44, 2229-2237, incorporated herein by reference).

7-tert-Butoxycarbonyl-2-exo-(2′-amino-3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane(7).

The bromination of 6 was performed using bromine in acetic acid asreported previously to provide the brominated intermediate 7 (seeCarroll, F. I. et al., J. Med. Chem., 2001, 44, 4039-4041, incorporatedherein by reference).

General Procedure for the Suzuki cross-coupling reaction (Compounds 8a,8b, 9a and 9b).

To a resealable reaction vessel under nitrogen was added 1.0 equiv ofthe bromo derivative 7, Pd(OAc)₂ (0.1 equiv), P(o-tolyl)₃ (0.2 equiv),sodium carbonate (2.0 equiv) and the respective pyridinyl boronic acid(1.6 equiv), DME (6 mL) and water (0.7 mL) The mixture was degassedthrough bubbling nitrogen and heated at 80° C. for 5 h. The mixture wascooled, poured into 20 mL of a saturated aqueous solution of NaHCO₃ andextracted with EtOAc (3×30 mL) The combined organic layers were driedover MgSO₄, filtered through Celite and the solvent removed underreduced pressure. The resultant residue was purified by flashchromatography (CHCl₃/MeOH, 50/1 to 10/1).

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(2-fluoropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(8a).

The reagents were compound 7 and 2-fluoropyridine-4-boronic acid. ¹H NMR(300 MHz, CDCl₃) δ 1.4 (br s, 9H), 1.52-1.59 (m, 2H), 1.82-1.84 (m, 3H),1.94-1.98 (m, 1H), 2.79-2.84 (m, 1H), 4.16 (s, 1H), 4.36 (br s, 1H),4.77 (s, 2 NH), 7.06 (s, 1H), 7.34 (ddd, J=1.6, 5.13, 8.4 Hz, 1H), 7.41(d, J=2.3 Hz, 1H), 8.0 (d, J=2.3 Hz, 1H), 8.26 (d, J=5.16 Hz, 1H); MS(ESI) m/z 385.3 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(2-chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(8b).

The reagents were compound 7 and 2-chloropyridine-4-boronic acid. ¹H NMR(300 MHz, CDCl₃) δ 1.41 (br s, 9H), 1.49-1.61 (m, 2H), 1.77-1.83 (m,3H), 1.94-2.00 (m, 1H), 2.78-2.83 (m, 1H), 4.16 (s, 1H), 4.36 (br s,1H), 4.54 (s, 2 NH), 7.37 (dd, J=1.4, 5.13 Hz, 1H), 7.40 (d, J=2.22 Hz,1H), 7.45 (s, 1H), 8.0 (d, J=2.22 Hz, 1H), 8.44 (d, J=5.10 Hz, 1H); ¹³CNMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.7, 40.5, 44.8, 55.9, 62.1, 79.6,117.4, 122.0, 123.8, 132.4, 136.5, 147.8, 149.6, 150.2, 152.4, 153.8,154.9; MS (ESI) m/z 401.3 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(6-fluoropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(9a).

The reagents were compound 7 and 5-fluoropyridine-4-boronic acid. ¹H NMR(300 MHz, CDCl₃) δ 1.39 (br s, 9H), 1.51-1.59 (m, 2H), 1.81-1.85 (m,3H), 1.94-2.00 (m, 1H), 2.79-2.84 (m, 1H), 4.16 (s, 1H), 4.35 (br s,1H), 4.70 (s, 2 NH), 7.02 (dd, J=2.9, 8.4 Hz, 1H), 7.34 (d, J=2.25 Hz,1H), 7.91 (ddd, J=2.5, 8.4, 16 Hz, 1H), 7.96 (d, J=2.25 Hz, 114), 8.28(d, J=2.4 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.2 (3 C), 28.8, 29.7, 40.3, 44.8,55.9, 62.1, 79.5, 109.5, 116.8, 132.0, 136.9, 141.5, 146.8, 147.5,154.6, 154.9, 161.3, 164.5; MS (ESI) m/z 385.5 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(6-chloropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(9b).

The reagents were compound 7 and 5-chloropyridine-4-boronic acid. ¹H NMR(300 MHz, CDCl₃) δ 1.31 (br s, 9H), 1.43-1.50 (m, 2H), 1.72-1.76 (m,3H), 1.85-1.92 (m, 1H), 2.70-2.74 (m, 1H), 4.06 (s, 1H), 4.26 (br s,1H), 4.60 (s, 2 NH), 7.25 (d, J=2.25 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H),7.71 (dd, J=2.5, 8.2 1H), 7.88 (d, J=2.2 Hz, 1H), 8.38 (d, J=2.2 Hz,1H); ¹³C NMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.7, 40.3, 44.8, 55.9, 62.1,79.5, 116.7, 124.2, 132.2, 133.1, 136.9, 139.0, 147.0, 149.5, 150.6,154.4, 155.0; MS (ESI) m/z 401.5 (M+H)⁺.

General Procedure for Diazotization and Simultaneous Removal of the BocProtecting Group (Compounds 10a, 10b, 11a and 11b).

A solution of the respective amino derivative (8a, 8b, 9a or 9b) in 70%HF-pyridine (1.5 mL) in a plastic reaction vessel was stirred at 0° C.for 30 min. Sodium nitrite (10 equiv) was then added in small portionsand the mixture stirred at room temperature for 1 h. The mixture wasthen poured into a solution of 1:1 NH₄OH/H₂O (40 mL) and extracted withEtOAc. The combined organic layers were dried over MgSO₄, filteredthrough Celite and concentrated in vacuo. The residue was purified byflash chromatography using CHCl₃/MeOH (10:1).

2-exo-[2′-Fluoro-3′-(2-fluoropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(10a).

Obtained in a 70% yield as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ1.56-1.68 (m, 6H), 1.92-1.98 (dd, J=9.1, 11.2 Hz, 1H), 2.81-2.86 (m,1H), 3.60 (s, 1H), 3.83 (br s 1H), 7.17 (d, J=1.0 Hz, 1H), 7.43 (ddd,J=1.6, 4.9, 6.9 Hz, 1H), 8.15-8.19 (m, 2H), 8.23 (d, J=5.3 Hz, 1H); ¹³CNMR (CDCl₃) δ 30.4, 31.5, 40.7, 44.2, 56.4, 62.9, 109.0, 119.4, 121.1,139.6, 141.5, 147.5, 157.1, 160.3, 162.6, 162.7; MS (ESI) m/z 288.3(M+H)⁺.

2-exo-[2′-Fluoro-3′-(2-chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(10b).

Obtained in an 87% yield as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ1.54-1.67 (m, 6H), 1.92-1.98 (dd, J=9.1, 11.2 Hz, 1H), 2.81-2.86 (m,1H), 3.60 (s, 1H), 3.83 (br s 1H), 7.46 (dd, J=1.2, 5.2 Hz, 1H), 7.56(s, 1H), 8.12-8.15 (m, 2H), 8.47 (d, J=5.2 Hz, 1H); ¹³C NMR (CDCl₃) δ30.4, 31.6, 40.7, 44.3, 56.4, 62.9, 119.2, 122.1, 139.6, 141.5, 145.1,147.2, 149.9, 152.1, 157.1, 160.3; MS (ESI) m/z 304.3 (M+H)⁺.

2-exo-[2′-Fluoro-3′-(6-fluoropyridirt-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(11a).

Obtained in a 66% yield as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ1.54-1.70 (m, 6H), 1.92-1.99 (dd, J=9.0, 11.2 Hz, 1H), 2.82-2.87 (m,1H), 3.61 (s, 1H), 3.83 (br s 1H), 7.04 (dd, J=3.0, 8.4 Hz, 1H),7.99-8.09 (m, 2H), 8.14 (br s, 1H), 8.42 (d, J=0.8 Hz, 1H); ¹³C NMR(CDCl₃) δ 30.3, 31.5, 40.6, 44.3, 56.4, 62.9, 109.3, 118.5, 139.5,141.3, 145.8, 147.5, 157.3, 160.4, 161.7, 164.9; MS (ESI) m/z 288.3(M+H)⁺.

2-exo-[2′-Fluoro-3′-(6-chloropyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(11b).

Obtained in a 62% yield as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ1.54-1.71 (m, 6H), 1.92-1.98 (dd, J=9.1, 11.2 Hz, 1H), 2.81-2.86 (m,1H), 3.61 (s, 1H), 3.81 (br s 1H), 7.42 (dd, J=0.6, 8.3 Hz, 1H), 7.88(ddd, J=0.8, 4.1, 8.3 Hz, 1H), 8.06 (dd, J=2.4, 9.6 Hz, 1H), 8.15 (br s,1H), 8.58 (br s, 1H); ¹³C NMR (CDCl₃) δ 30.4, 31.5, 40.6, 44.3, 56.4,62.9, 118.5, 124.1, 129.2, 139.5, 141.3, 146.1, 149.2, 151.2, 157.3,160.5; MS (ESI) m/z 304.3 (M+H)⁺.

General Procedure for Fumarate Salt Formation (Analogues 12a, 12b, 13aand 13b).

A solution of the respective amine (10a, 10b, 11a or 11b) in ether (3mL) in a vial was treated with a 1.3 equiv of fumaric acid (0.65 M) inMeOH and allowed to stand in a refrigerator overnight. The excess etherwas then removed under reduced pressure and the residue salt wasredissolved in a minimal amount of MeOH. The fumarate salts wererecrystallized from MeOH using diethyl ether.

2′-Fluoro-3′-(2″-fluoro-4″-pyridinyl)deschloroepibatidine fumarate (12a).

Obtained in a 55% yield as a white crystalline solid afterrecrystallization: mp. 203-205° C.; ¹H NMR (500 MHz, CD₃OD) δ 1.87-2.20(m, 5H), 2.45-2.50 (dd, J=9.3, 13.2 Hz, 1H), 3.50-3.53 (m, 1H),4.34-4.35 (br s, 1H), 4.56 (d, J=3.9 Hz, 1H), 6.64 (s, 2H), 7.41 (s,1H), 7.61-7.63 (m, 1H), 8.21 (dd, J=2.4, 9.3 Hz, 1H), 8.28 (d, J=1.0 Hz,1H), 8.32 (d, J=5.3 Hz, 1H); ¹³C NMR (CD₃OD) δ 25.8, 27.8, 36.5, 42.2,59.0, 62.8, 109.4, 121.6, 135.0, 136.5, 140.1, 147.2, 147.8, 158.3,160.2, 163.4, 165.3, 170.2; MS (ESI) m/z 288.3 [(M−fumaric)⁺,M=C₁₆H₁₅F₂N₃.C₄H₄O₄]; Anal. (C₂₀H₁₉P₂N₃O₄) C, H, N.

2′-Fluoro-3′-(2″-chloro-4″-pyridinyl)deschloroepibatidine fumarate(12b).

Obtained in a 42% yield as a white crystalline solid afterrecrystallization: mp. 193-194° C.; ¹H NMR (500 MHz, CD₃OD) δ 1.87-2.21(m, 5H), 2.45-2.50 (dd, J=9.2, 13.2 Hz, 1H), 3.50-3.53 (m, 1H),4.34-4.35 (br s, 1H), 4.56 (d, J=3.9 Hz, 1H), 6.63 (s, 2H), 7.67 (dd,J=1.4, 9.3 Hz, 1H), 7.80 (s, 1H), 8.21 (dd, J=2.4, 9.3 Hz, 1H), 8.28 (d,J=2.4 Hz, 1H), 8.48 (d, J=4.9 Hz, 1H); ¹³C NMR (CD₃OD) δ 25.7, 27.8,36.5, 42.2, 59.0, 62.9, 119.4, 122.7, 135.0, 136.6, 140.1, 145.4, 147.3,149.9, 151.8, 158.3, 160.3, 170.1; MS (ESI) m/z 304.0 [(M−fumaric)⁺,M=C₁₆H₁₅ClFN₃.C₄H₄O₄]; Anal. (C₂₀H₁₉ClFN₃O₄.0.25 H₂O) C, H, N.

2′-Fluoro-3′-(2″-fluoro-5″-pyridinyl)deschloroepibatidine hemifumar ate(13a).

Obtained in a 33% yield as a white crystalline solid afterrecrystallization: mp. 197-199° C.; ¹H NMR (500 MHz, CD₃OD) δ 1.81-2.15(m, 5H), 2.38-2.43 (dd, J=9.3, 13.2 Hz, 1H), 3.42-3.46 (m, 1H), 4.43 (brs, 1H), 6.57 (s, 1H), 7.21 (dd, J=2.4, 8.3 Hz 1H), 8.14 (dd, J=2.4, 8.2Hz, 1H), 8.21-8.25 (m, 2H), 8.48 (br s, 1H); ¹³C NMR (CD₃OD) δ 27.5,29.5, 38.3, 43.8, 59.9, 64.1, 111.0, 120.5, 129.6, 137.0, 138.4, 141.4,143.8, 147.2, 148.8, 159.7, 161.6, 164.1, 166.0, 174.0; MS (ESI) m/z288.3 [(M−fumaric)⁺, M=C₁₆H₁₅F₂N₃.0.5C₄H₄O₄]; Anal. (C₁₈H₁₇F₂N₃O₂) C, H,N.

2′-Fluoro-3′-(2″-chloro-5″-pyridinyl)deschloroepibatidine fumarate(13b).

Obtained in a 55% yield as a white crystalline solid afterrecrystallization: mp. 194-195° C.; ¹H NMR (500 MHz, CD₃OD) δ 1.89-2.20(m, 5H), 2.45-2.49 (dd, J=9.2, 13.2 Hz, 1H), 3.49-3.52 (dd, J=3.5, 9.5Hz, 1H), 4.34 (br s, 1H), 4.56 (d, J=3.5 Hz, 1H), 6.63 (s, 2H), 7.60 (d,J=8.5 Hz, 1H), 8.09-8.15 (m, 2H), 8.23 (d, J=2.4 Hz, 1H), 8.64 (br s,1H); ¹³C NMR (CD₃OD) δ 27.1, 29.1, 37.8, 43.5, 60.3, 64.2, 120.4, 125.8,130.6, 136.3, 137.8, 141.3, 147.4, 150.6, 152.6, 159.8, 161.7, 171.5; MS(ESI) m/z 304.5 [(M−fumaric)⁺, M=C₁₆H₁₅ClFN₃.C₄H₄O₄]; Anal.(C₂₀H₁₉ClFN₃O₄) C, H, N.

Example 2 Synthesis of 2′-(Pyridinyl and Methoxypyridinyl Substituted)Epibatidine Analogues

These exemplary procedures relate to the synthesis of fumarate salts ofanalogues, containing pyridinyl ring substitution and 2-methoxypyridinyl ring substitution. The brominated intermediate, 7,(7-tert-butoxycarbonyl-2-exo-(2′-amino-3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane)was prepared as previously described in Example 1 and the referencestherein. Scheme 3 outlines the route to the analogues discussed in thisexample. Suzuki cross-coupling reactions of bromo intermediate 7 withthe respective pyridinyl boronic acids, in the presence of Pd(PPh₃)₄ asthe catalyst, K₂CO₃ as the base and toluene (15 mL), ethanol (1.5 mL)and water (1 5 mL) as solvents, heated at reflux for 24 h in a sealedtube provided the cross-coupled products (14a, 14b, 15a, 15b and 16) ingood yields. Diazotization reactions using 70% HF in pyridinesuccessfully converted the amine to a flouro group with simultaneousremoval of the BOC group in the case of the pyridinyl and2-methoxypyridinyl analogues furnishing the free base amine derivatives(17a, 17b, 18a, 18b, and 19), in good yields. The fumarate salts of therespective amines were prepared and recrystallized from MeOH/ether tofurnish the epibatidine analogues as fumarate salts 20a, 20b and 21respectively.

Experimental Procedure:

General Procedure for the Synthesis of 14a, 14b, 15a, 15b and 16.

To a resealable reaction vessel under nitrogen was added 1.0 equiv of 7,Pd(PPh₃)₄, K₂CO₃ (2.0 equiv) and the respective boronic acid (1.3equiv), toluene (12 mL), ethanol (1.5 mL) and water (1.5 mL). Themixture was degassed through bubbling nitrogen and heated at 110° C.After 24 h, the mixture was cooled, poured into 30 mL of H₂O andextracted with EtOAc (3×30 mL) The combined organic layers were driedover MgSO₄, filtered through Celite and the solvent was removed invacuo. The resultant residue was purified by flash chromatography usinghexanes/isopropanol (80/20 to 25/75) in the case of the pyridine analogs(14a and 14b) or CHCl₃/MeOH (30/1 to 10/1) in the case of carbamoyl andmethoxy pyridine analogs (15a, 15b, and 16).

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(pyridin-4-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(14a).

The reagents were compound 7 and pyridine-4-boronic acid. ¹H NMR (300MHz, CDCl₃) δ 1.39 (br s, 9H), 1.44-1.59 (m, 2H), 1.81-1.84 (m, 3H),1.93-2.00 (m, 1H), 2.79-2.84 (dd, J=3.8, 5.0 Hz, 1H), 4.16 (s, 1H), 4.36(br s, 1H), 4.67 (s, 2 NH), 7.39-7.43 (m, 3H), 7.99 (d, J=2.3 Hz, 1H),8.66 (dd, J=6.0, 1.5 Hz, 1H); ¹³C NMR (CDCl₃) δ; 28.3 (3 C), 40.4, 44.8,55.8, 62.1, 79.5, 118.7, 123.4, 132.2, 136.5, 146.4, 147.2, 150.5,153.9, 154.9; MS (ESI) m/z 367.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(pyridin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(14b).

The reagents were compound 7 and pyridine-3-boronic acid. ¹H NMR (300MHz, CDCl₃) δ 1.41 (br s, 9H), 1.48-1.61 (m, 2H), 1.75-1.86 (m, 3H),1.96-2.04 (m, 1H), 2.79-2.83 (dd, J=3.8, 5.0 Hz, 1H), 4.16 (s, 1H), 4.35(br s, 1H), 4.66 (s, 2 NH), 7.34 (d, J=2.5 Hz, 1H), 7.38 (d, J=4.9 Hz,1H), 7.80 (dt, J=7.9, 1.9 Hz, 1H), 7.96 (d, J=2.2 Hz, 1H), 8.59 (dd,J=4.9, 1.6 Hz, 1H), 8.69 (d, J=1.8 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.3 (3C), 28.8, 29.7, 40.3, 44.9, 55.9, 62.2, 79.5, 118.0, 123.6, 132.1,134.1, 136.2, 136.9, 146.6, 148.9, 149.7, 154.5, 154.9; MS (ESI) m/z367.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(3-aminocarbonylphenyl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(15a).

The reagents were compound 7 and 3-carbamoylphenyboronic acid. ¹H NMR(300 MHz, CD₃OD) δ 1.37 (br s, 9H), 1.49-1.59 (m, 2H), 1.74-1.88 (m,3H), 1.90-1.97 (m, 1H), 2.91-2.96 (dd, J=4.0, 4.7 Hz,1H), 4.16 (s, 1H),4.33 (br s, 1H), 7.40 (d, J=2.3, Hz, 1H), 7.56 (t, J=7.6 Hz, 1H), 7.65(dt, J=7.8, 1.5 Hz, 1H), 7.86 (d, J=2.2 Hz, 1H), 7.91 (dt, J=7.6, 1.6Hz, 1H), 7.96 (t, J=1.5 Hz 1H); ¹³C NMR (CD₃OD) δ 28.6 (3 C), 29.8,30.5, 40.9, 45.9, 57.2, 63.6, 66.9, 81.2, 122.8, 128.4, 129.1, 130.4,132.7, 133.2, 136.0, 138.8, 139.8, 145.9, 156.2, 156.4, 172.0; MS (ESI)m/z 409.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(4-aminocarbonylphenyl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(15b).

The reagents were compound 7 and 4-carbamoylphenylboronic acid. ¹H NMR(300 MHz, CDCl₃) δ 1.38 (br s, 9H), 1.51-1.58 (m, 2H), 1.81-1.86 (m,3H), 1.93-2.03 (m, 1H), 2.78-2.83 (dd, J=3.8, 4.9 Hz,1H), 4.11 (s, 1H),4.35 (br s, 1H), 4.6 (s, 2NH), 6.32-6.44 (br s, H, 2H), 7.37 (d, J=2.3,Hz, 1H), 7.53 (dt, J=8.4, 1.9 Hz, 2H), 7.92 (td, J=8.4, 1.7 Hz, 2H),7.95 (d, J=2.3 Hz, 1H);

¹³C NMR (CDCl₃) δ 28.4 (3 C), 29.0, 29.9, 40.4, 45.1, 56.0, 60.5, 62.3,79.7, 120.6, 128.3, 129.0, 132.1, 132.9, 136.8, 142.1, 146.3, 154.4,155.1, 169.3; MS (ESI) m/z 409.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(6-methoxypyridin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(16).

The reagents were compound 7 and 2-methoxy-5-pyridineboronic acid. ¹HNMR (300 MHz, CDCl₃) δ 1.39 (br s, 9H), 1.50-1.59 (m, 2H), 1.76-1.88 (m,3H), 1.91-1.98 (m, 1H), 2.77-2.81 (dd, J=3.7, 5.0 Hz, 1H), 3.94 (s, 3H),4.16 (s, 1H), 4.34 (br s, 1H), 4.78 (s, 2 NH), 6.79 (d, J=8.5 Hz, 1H),7.30 (d, J=2.3 Hz, 1H), 7.65 (dd, J=8.4, 2.4 Hz, 1H), 7.93 (d, J=2.3 Hz,1H) 8.22 (d, J=2.3 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.1 (3 C), 28.4, 28.6,40.1, 44.8, 53.3, 55.3, 62.1, 79.3, 110.8, 118.1, 126.9, 128.4, 131.8,136.7, 138.9, 145.8, 146.6, 154.8, 163.5; MS (ESI) m/z 397.5 (M+H)⁺.

General Procedure for Diazotization and Simultaneous Removal of the BocProtecting Group (Compounds 17a, 17b, 18a, 18b and 19).

A solution of the respective amino derivative (14a, 14b, 15a, 15b or 16)in 70% HF-pyridine (1.5 mL) in a plastic reaction vessel was stirred at0° C. for 30 min Sodium nitrite (10 equiv) was then added in smallportions and the mixture stirred at room temperature. After 1 h, themixture was poured into a 1:1 aqueous solution of NH₄OH/H₂O (40 mL) andextracted with EtOAc (3×40 mL). The combined organic layers were driedover MgSO₄, filtered through Celite and concentrated in vacuo. Theresultant residue was purified by flash chromatography using CHCl₃/MeOH(10:1).

2-exo-[2′-Fluoro-3′-(pyridin-4-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(17a).

Obtained in a 69% yield as a colorless oil. ¹H NMR (300 MHz, CD₃OD) δ1.50-1.78 (m, 6H), 2.01-2.08 (dd, J=9.0, 11.2 Hz, 1H), 3.02-3.07 (dd,J=8.7, 5.2 Hz,1H), 3.66 (s, 1H), 3.77 (br s 1H), 7.70-7.73 (m, 2H), 8.13(dd, J=2.4, 9.4 Hz, 1H), 8.18 (s, 1H), 8.64 (d, J=1.5 Hz, 1H), 8.65 (d,J=1.5 Hz, 1H); ¹³C NMR (CD₃OD) δ 30.0, 31.8, 41.1, 45.7, 57.9, 63.7,121.2, 125.1, 141.3, 142.1, 144.2, 147.8, 148.0, 150.6, 158.6, 161.7; MS(ESI) m/z 270.2 (M+H)⁺.

2-exo-[2′-Fluoro-3′-(pyridin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(17b).

Obtained in 70% yield as a colorless oil. ¹H NMR (300 MHz, CD₃OD) δ1.49-1.79 (m, 6H), 2.01-2.08 (dd, J=9.1, 11.2 Hz, 1H), 3.02-3.07 (dd,J=3.3, 5.4 Hz, 1H), 3.67 (s, 1H), 3.77 (br s 1H), 7.54 (dd, J=2.6, 7.8Hz, 1H), 8.08-8.15 (m, 3H), 8.58-8.60 (d, 2H), 8.58 (d, J=1.4 Hz, 1H),8.80 (s, 1H); ¹³C NMR (CD₃OD) δ 29.9, 31.8, 40.6, 41.1, 45.7, 57.8,63.9, 121.1, 125.2, 138.4, 141.4, 142.0, 147.0, 149.9, 150.1, 158.7,161.8; MS (ESI) m/z 270.3 (M+H)⁺.

2-exo-[2′-Fluoro-3′-(6-methoxypyridin-3-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(19).

Obtained in a 73% yield as a colorless oil. ¹H NMR (300 MHz, CD₃OD) δ1.48-1.76 (m, 6H), 1.94-2.05 (m, 2H), 2.96-3.01 (dd, J=3.4, 5.5 Hz, 1H),3.65 (s, 1H), 3.77 (br s 1H), 6.83 (d, J=8.7 Hz, 1H), 7.88 (tt, J=0.7,1.7, 8.7 Hz, 1H), 7.99 (dd, J=2.4, 9.6 Hz, 1H), 8.04 (d, J=0.8 Hz, 1H),8.34 (d, J=1.6 Hz, 1H); ¹³C NMR (CD₃OD) δ 29.9, 31.7, 40.9, 45.7, 54.3,57.7, 63.7, 111.7, 121.3, 124.5, 140.8, 141.6, 145.8, 147.9, 158.6,161.8, 165.5; MS (ESI) m/z 300.3 (M+H)⁺.

Example 3 Synthesis of Epibatidine Analogs—Pyridinyl, Methoxy Pyridinyland Carbamoyl Phenyl Substituted Analogs

Heck cross-coupling of monoolefin 4 with 2-amino-5-iodopyridine, 5, wasdone as reported in earlier examples to provide intermediate 6 which wassubsequently subjected to bromination at the C-3 position ortho to theamino group to provide 7(7-tert-butoxycarbonyl-2-exo-(2′-amino-3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane).For the synthesis of the pyridinyl and methoxy pyridinyl analogs, 7 wassubjected to the Suzuki cross-coupling reactions with the respectivepyridinyl boronic acids in the presence of Pd(PPh₃)₄ as the catalyst,K₂CO₃ as the base and toluene (15 mL), ethanol (1.5 mL) and water (1.5mL) as solvents as shown in the Scheme 4 below. The reactions wereheated at reflux for 24 h in a sealed tube to provide the cross-coupledproducts in good yields. Diazotization reactions using 70% HF inpyridine successfully converted the amino to a fluoro group withsimultaneous removal of the BOC group. The fumarate salts of therespective amines were prepared and recrystallized from Me0H/ ether tofurnish the epibatidine analogs as fumarate salts 20a, 20b and 21respectively as discussed in Example 2 above.

In the case of carbamoyl phenyl analogs, the brominated intermediate 7,was first subjected to a diazonium reaction converting the amino groupto a Fluoro group along with the simultaneous removal of the t-Boc groupto provide the amine intermediate. The Suzuki cross-coupling of theamine intermediate with the respective carbamoyl phenyl boronic acidsprovided the amine analogs 18a and 18b. Hydrochloride salts of theamines were prepared to provide analogs 22a and 22b.

Experimental Procedure: General Procedure for Fumarate Salt Formation(Analogues 20a, 20b and 21).

A solution of the respective amine (17a, 17b, or 19) in methanol (1 mL)in a vial was treated with a 1.1 equiv of fumaric acid (0.65 M) in MeOHand left standing overnight in a refrigerator. Excess ether was removedunder reduced pressure and the resultant salt was redissolved in minimalamount of MeOH. The fumarate salts were recrystallized from MeOH usingdiethyl ether.

2′-Fluoro-3′-(4″-pyridinyl)deschloroepibatidine fumarate (20a).

Mp. 192-195° C. ¹H NMR (300 MHz, CD₃OD) δ 1.86-2.22 (m, 6H), 2.44-2.51(dd, J=9.0, 11.0 Hz, 1H), 3.50-3.55 (m, 1H), 4.35 (br s, 1H), 4.56 (d,J=3.9 Hz, 1H), 6.63 (s, 1H), 7.72-7.75 (m, 2H), 8.20 (dd, J=2.4, 9.0 Hz,1H), 8.27 (d, J=2.4 Hz, 1H), 8.67 (m, 2H); ¹³C NMR (CD₃OD) δ 27.0, 29.0,37.7, 43.4, 60.2, 64.1, 121.6, 125.1, 136.2, 137.6, 141.3, 147.8, 148.0,150.7, 159.0, 162.2, 171.4; MS (ESI) m/z 270.1 [(M−fumaric)⁺,M=C₁₆H₁₆FN₃.C₄H₄O₄]; Anal. (C₂₀H₂₀FN₃O₄.0.25 H₂O) C, H, N.

2′-Fluoro-3′-(3″-pyridinyl)deschloroepibatidine hemifumarate (20b).

Mp. 155-159° C. ¹HNMR (300 MHz, CD₃OD) δ 1.86-2.22 (m, 6H), 2.44-2.51(dd, J=9.0, 11.0 Hz, 1H), 3.49-3.54 (dd, J=3.0, 5.1 Hz, 1H), 4.35 (br s,1H), 4.56 (d, J=3.9 Hz, 1H), 6.63 (s, 1H), 7.56-7.60 (dd, J=2.3, 7.5 Hz,1H), 8.12-8.16 (m, 2H), 8.23 (s, 1H), 8.61 (dd, J=1.4, 6.0 Hz, 1H), 8.81(s, 1H); ¹³C NMR (CD₃OD) δ 27.4, 29.4, 38.2, 43.8, 59.8, 64.0, 121.0,125.4, 136.8, 138.2, 138.5, 141.4, 147.0, 147.2, 150.0, 159.1, 162.3,171.5; MS (ESI) m/z 270.2 [(M−fumaric)⁺, M=C₁₆H₁₆FN₃.0.5C₄H₄O₄]; Anal.(C₁₈H₁₈FN₃O₂.0.5 H₂O) C, H, N.

2′-Fluoro-3′-(2″-methoxy-5″-pyridinyl)deschloroepibatidine hemifumarate(21).

Mp. 193-195° C. ¹H NMR (300 MHz, CD₃OD) δ 1.80-2.15 (m, 6H), 2.36-2.43(dd, J=9.3, 13.2 Hz, 1H), 3.40-3.45 (m, 1H), 3.96 (s, 3H), 4.27 (br s,1H), 4.42 (s, 1H), 6.61 (s, 1H), 6.91 (dd, J=0.7, 7.6 Hz 1H), 7.95 (dt,J=0.8, 2.4, 8.8 Hz, 1H), 8.06 (dd, J=1.9, 8.8 Hz, 1H), 8.14 (d, J=1.9Hz, 1H), 8.41 (br s, 1H); ¹³C NMR (CD₃OD) δ 27.4, 29.4, 38.3, 43.8,54.3, 59.8, 64.0, 111.7, 124.2, 136.8, 138.1, 140.76, 145.8, 148.0,159.1, 162.2, 165.7, 176.3; MS (ESI) m/z 300.5 [(M−fumaric)⁺,M=C₁₇H₁₈FN₃O.0.5C₄H₄O₄]; Anal. (C₁₉H₂₀FN₃O₃.0.25 H₂O) C, H, N.

2-exo-[2′-Fluoro-3′-(4-aminocarbonylphenyl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(18a).

Obtained in a 78% yield as a colorless oil.

¹H NMR (300 MHz, CDCl₃) δ 1.53-1.72 (m, 5H), 1.91-1.98 (m, 3H),2.82-2.86 (m, 1H), 3.61(s, 1H), 3.80 (s, 1H), 6.58 (br s, 2H), 7.62-7.65(m, 2H), 7.89-7.92 (m, 2H), 8.01 (dd, J=2.4, 9.6 Hz, 1H), 8.10 (s, 1H);¹³C NMR (CDCl₃) δ 30.2, 40.5, 44.4, 56.4, 62.8, 122.2, 127.1, 129.0,133.1, 137.8, 139.8, 140.8, 145.6, 160.5, 169.1; MS (ESI) m/z 312.6(M+H)⁺.

2-exo-[2′-Fluoro-3′-(3-aminocarbonylphenyl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane (18b).

Obtained in a 79% yield as a colorless oil.

¹H NMR (300 MHz, CD₃OD) δ 1.46-1.74 (m, 5H), 1.99-2.03 (m, 1H),2.95-3.00 (m, 1H), 3.62 (s, 1H), 3.74 (s, 1H), 7.54 (t, J=7.8 Hz 1H),7.77 (dt, J=1.2, 7.8 Hz, 1H), 7.91 (dt, J=1.1, 7.8 Hz, 1H), 8.01 (dd,J=2.3, 9.6 Hz, 1H), 8.06 (s, 1H), 8.11(s, 1H); ¹³C NMR (CD₃OD) δ 29.9,31.8, 41.1, 45.7, 57.8, 63.7, 123.6, 128.7, 129.2, 130.0, 133.3, 132.9,135.6, 141.4, 146.3, 158.6, 161.8, 171.7; MS (ESI) m/z 312.6 (M+H)⁺.

General Procedure for the Hydrochloride Salts Formation of the BenzamideAnalogs 22a and 22b

A solution of the amine benzamides (18a or 18b) in chloroform in a vialwas treated with a 1.0 equivalent of HCl in diethyl ether. The excesssolvent was removed in vacuo and the salt dried under vacuum.

2-exo-2-Fluoro-3-(4′-benzamide)deschloroepibatidine Hydrochloride (22a).

Obtained as a white solid in 99% yield. M.p 202-206° C. ¹H NMR (300 MHz,CD₃OD) δ 1.91-2.20 (m, 5H), 2.46-2.54 (dd, J=3.8, 9.6 Hz, 1H), 3.51-3.56(m, 1H), 4.35, (d, J=3.5 Hz, 1H), 4.60 (d, J=2.5 Hz, 1H), 7.77-7.74 (m,2H), 7.99-8.02 (m, 2H), 8.10 (dd, J=2.4, 9.2 Hz, 1H), 8.20 (s, 1H); ¹³CNMR (CD₃OD) δ 26.8, 28.9, 37.6, 43.3, 60.5, 64.3, 123.8, 129.1, 130.2,135.0, 137.2, 138.3, 141.4, 146.4, 159.1, 162.3, 171.6; MS (ESI) m/z312.4 [(M−HCl),⁺, M=C₁₈H₁₈FN₃O .HCl]; Anal. (C₁₈H₁₉ClFN₃O.1.75 H₂O) C,H, N.

2-exo-2-Fluoro-3-(3′-benzamide)deschloroepibatidine Hydrochloride (22b).

Obtained in a 99% yield as a white solid. ¹H NMR (300 MHz, CD₃OD)δ1.99-2.24 (m, 5H), 2.45-2.53 (dd, J=3.8, 9.6 Hz, 1H), 3.51-3.56 (m,1H), 4.36, (d, J=3.5 Hz, 1H), 4.60 (d, J=2.5 Hz, 1H), 7.59 (t, J=7.8 Hz1H), 7.83 (dt, J=1.2, 7.8 Hz, 1H), 7.95 (dt, J=1.2, 7.8 Hz, 1H),8.13-8.20 (m, 3H); ¹³C NMR (CD₃OD) δ 26.8, 28.9, 37.6, 43.3, 60.5, 64.3,124.4, 128.8, 129.4, 130.0, 133.4, 135.4, 137.2, 141.4, 146.4, 159.1,162.3, 171.7; MS (ESI) m/z 312.5 [(M−HCl)⁺, M=C₁₈H₁₈FN₃O.HCl];. Anal.(C₁₈H₁₉ClFN₃O.2.5 H₂O) C, H, N.

Example 4 Synthesis of Epibatidine Analogues—Pyridinyl, MethoxyPyridinyl, and Amino Pyridinyl Substituted Analogues

In the exemplary procedures discussed in this example, the brominatedintermediate 7, was first subjected to a diazonium/ Sandmeyer reactionusing HF in pyridine to convert the amino group to a Fluoro group alongwith the simultaneous removal of the t-Boc group to provide theintermediate 23. The synthesis of the amino pyridinyl analogue wasachieved via a Miyaura cross-coupling reaction between intermediate 23and the commercially available 2-amino pyridine-5-pinacol boronic ester,24 (Scheme 5). The cross-coupling was accomplished using Pd(PPh₃)₄ as acatalyst, K₂CO₃ as the base, dioxane as the solvent with catalyticamounts of water and heated at 110° C. in a sealed tube overnight toprovide the diamine 25 in a 67% yield. The diamine 25 was converted intothe HCl salt 26 using HCl in diethyl ether.

There are two possible routes for the preparation of2-methoxypyridine-4-pinacol boronic ester, 32, a known compound, asshown in Schemes 6 (see Fraley, M. E. et al., Bioorg. Med. Chem. Lett.2002, 12, 3537-3541, incorporated herein by reference) and 7 (seeMorgentin, R. et al., Tetrahedron, 2008, 64, 2772-2780, incorporatedherein by reference). The alternate route for the synthesis of4-amino-2-methoxypyridine, 30, (Scheme 7) was sought due to the lowyields obtained in the nitration step of Scheme 6. Cross-coupling of 34with bis(pinacolata)diborane in the presence of potassium acetate as thebase and PdCl₂(dppf) as the catalyst and heated in DMF at 80° C.overnight provided the boronic ester 32 in a 74% yield.

The methoxy substituted analogue 35 was obtained from the cross-couplingof 23 and the boronic ester 32 (Scheme 8 below) in a 50% yield. Theamine analogue 35 was converted to the fumarate salt 36, using fumaricacid in MeOH and recrystallized using diethylether.

Several different conditions for the synthesis of 38 were investigatedand the successful synthesis involved a “one-pot” reaction protocol thatcombined the borylation and the Suzuki-Miyaura using Buchwald's ligand,Xphos (2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) (seeBillingsley, K. L. et al., Angew. Chem. Int. Ed., 2007, 46, 5359-5363;Martin, T. et al., Org. Lett., 2009, 11, 3690-3693, both incorporatedherein by reference). Following a protocol similar to the citedreference, the borylation reaction was accomplished by cross-coupling ofcommercially available 2-amino-4-bromopryidine (37) andbis(pinacolata)diborane, XPhos, and Pd₂dba₃ as catalyst. The reactionwas heated at 110° C. in dioxanes in the presence of 3.0 equivalents ofKOAc and monitored by TLC and until all the starting material wasconverted to the boronic ester after 4 hours. The boronic ester wascarried on to the next step directly by addition of 23, K₃PO₄ as baseand an additional 3 mol % of Pd₂dba₃. The reaction was heated at 110° C.for an additional 18 h to provide the desired product 39 in 21% yield(Scheme 9). The amine was converted to the hydrochloride salt using HClin diethylether to furnish 40 in a quantitative yield.

Experimental Procedures: Procedure for Diazotization/Sandmeyer Reactionsand Simultaneous Removal of the Boc Protecting Group (Compound 23).

A solution of the respective amino derivative 7, in 70% HF-pyridine(1.5-3 mL) in a plastic reaction vessel was stirred at 0° C. for 30 min.Sodium nitrite (10 equiv) was then added in small portions and themixture stirred at room temperature for 1 h. The mixture was then pouredinto a solution of 1:1 NH₄OH/H₂O (60 mL) and extracted with CHCl₃. Thecombined organic layers were dried over MgSO₄, filtered through Celiteand concentrated in vacuo. The residue was purified by flashchromatography using CHCl₃/MeOH (10:1).

2-exo-[2′-Fluoro-3′-bromo-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane,(23).

Obtained in a 90% yield as a colorless oil. ¹H NMR (300 MHz, CD₃OD) δ1.47-1.68 (m, 6H), 1.96-2.03 (m, 2H), 2.92-2.96 (dd, J=3.4, 5.5 Hz, 1H),3.59 (s, 1H), 3.75 (br s 1H), 8.06 (d, J=2.4 Hz, 1H), 8.17 (dd, J=2.4,8.8 Hz, 1H); ¹³C NMR (CD₃OD) δ 30.1, 31.8, 41.2, 45.5, 57.8, 63.6 105.0,143.2, 145.9, 147.9, 157.9, 161.0; MS (ESI) m/z 271.2, 273.3 (M+H)⁺.

Procedures for the Synthesis of Amino and Methoxy Substituted Compounds25 and 35 and their Fumarate Salts 26 and 36.

To a resealable reaction pressure vessel under nitrogen was added 1.0equiv of 2-exo-(2′-amino-3′-bromo)-7-azabicyclo[2.2.1]heptane, Pd(PPh₃)₄(5 mol %), K₂CO₃ (2.0 equiv), dioxane (10 mL), water (0.80 mL), and therespective boronic ester (1.3 equiv). The mixture was degassed throughbubbling nitrogen for 40 min and heated at 110° C. for 18 h. Aftercooling, the solvent was removed under reduced pressure and to theresidue was added 20 mL of H₂O. The organic product was extracted usingEtOAc (3×30 mL). The combined organic layers were dried over MgSO₄,filtered through Celite and the solvent removed in vacuo. Purificationby flash chromatography using MeOH/CHCl₃ provided the desired products25 and 35 as colorless oils in yields of 67% and 50% respectively.

2′-Fluoro-3′-(2″-amino-5″-pyridinyl)deschloroepibatidine (25)

¹H NMR (300 MHz, CDCl₃) δ 1.47-1.67 (m, 5H), 1.85-1.92 (m, 2H),2.76-2.80 (dd, J=3.8, 5.0 Hz, 1H), 3.56 (s, 1H), 3.75 (d, J=2.7 Hz, 1H),4.82 (s, 2H), 6.53 (d, J=8.6 Hz, 1H), 7.63 (dt, J=1.9, 8.6 Hz, 1H), 7.87(dd, J=2.3, 9.5 Hz, 1H), 7.98 (s, 1H), 8.23 (s, 1H); ¹³CNMR (CDCl₃) δ30.2, 31.4, 40.5, 44.5, 56.4, 62.8, 108.2, 120.2, 138.0, 138.7, 140.7,144.2, 147.9, 157.5, 158.3, 160.6; MS (ESI) m/z 285.7 (M+H)⁺.

2′-Fluoro-3′-(2″-amino-5″-pyridinyl)deschloroepibatidine hydrochloride(26).

A solution of the diamine 25 in chloroform in a vial was treated with a2.0 equivalents solution of HCl in diethyl ether and allowed to stand atroom temperature. The excess solvent was filtered off and the obtainedsalt washed with ether and then dried to provide a 90% yield of the saltas a white solid. Mp. 202-205° C. ¹H NMR (300 MHz, CD₃OD) δ 1.88-2.24(m, 5H), 2.44-2.52 (dd, J=3.8, 9.6 Hz, 1H), 3.51-3.56 (dd, J=3.1, 5.5Hz, 1H), 4.37 (d, J=3.4 Hz, 1H), 4.58 (d, J=2.7 Hz, 1H), 7.11 (dd,J=1.9, 8.2 Hz, 1H), 8.18-8.28 (m 4H); ¹³CNMR (CD₃OD) δ 26.8, 28.9, 37.6,43.3, 60.5, 64.4, 114.7, 119.3, 120.4, 137.6, 140.6, 145.1, 147.2,155.8, 158.9, 162.1; MS (ESI) m/z 285.6 [(M−HCl)⁺, M=C₁₆H₁₇FN₄.2HCl];Anal. (C₁₆H₁₉Cl₂FN₄.1.25 H₂O) C, H, N.

2-exo-[2′-Fluoro-3′-(2-methoxypyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(35).

¹H NMR (300 MHz, CDCl₃) δ 1.51-1.68 (m, 5H), 1.89-1.96 (dd, 3.8, 9.6 Hz,1H), 1.98 (broad signal 1H), 2.79-2.84 (dd, J=3.4, 5.5 Hz, 1H), 3.59 (s,1H), 3.81 (s, 1H), 3.96 (s, 3 H), 6.96 (s, 1H), 7.07-7.10 (dt, J=5.3,1.5 Hz, 1H), 8.06 (dd, J=2.4, 9.6 Hz, 1H), 8.11 (s, 1H), 8.21 (d, J=5.3Hz, 1H); ¹³C NMR (CDCl₃) δ 30.2. 31.4, 40.5, 44.3, 53.5, 56.4, 62.9,110.5, 116.6, 139.6, 140.8, 144.6, 146.2, 146.4, 147.2, 160.5, 164.6; MS(ESI) m/z (300.4) (M+H)⁺.

2-Fluoro-3-(2′-methoxy-4′-pyridinyl)deschloroepibatidine fumarate (36).

A solution of 35 in CH₂Cl₂ in a vial was treated with a 1.2 equiv offumaric acid (0.65 M) in MeOH and the vial was allowed to stand in arefrigerator overnight. The excess solvent was then removed in vacuofrom the salt and then redissolved in minimal amount of MeOH and thefumarates salt was recrystallized from MeOH using diethyl ether. Mp.160-164° C. ¹H NMR (300 MHz, CD₃OD) δ 1.85-2.19 (m, 5H), 2.43-2.50 (dd,J=9.3, 13.2 Hz, 1H), 3.48-3.53 (m, 1H), 3.96 (s, 3H), 4.34 (br s, 1H),4.55 (s, 1H), 6.65 (s, 2H), 7.07 (s, 1H), 7.22 (dd, J=1.2, 4.1 Hz 1H),8.12 (d, J=9.2 Hz, 1H), 8.22-8.23 (m 2H); ¹³C NMR (CD₃OD) δ 26.9, 29.0,37.7, 43.4, 54.2, 60.2, 64.1, 111.6, 117.9, 136.1, 137.5, 141.2, 147.5,147.6, 148.3, 166.2, 171.1; MS (ESI) m/z 300.3 [(M−fumaric)⁺,M=C₁₇H₁₈FN₃O.C₄H₄O₄]; Anal. (C₂₁H₂₂FN₃O₅) C, H, N.

2-Fluoro-3-(2′-amino-4′-pyridinyl)deschloroepibatidine (39).

A solution of 2-amino-4-bromopyridine (1.16 mmol, 1.0 equiv),bispinacolata diborane (1.21 mmol, 1.05 equiv), Pd₂dba₃ (0.035 mmol, 3mol %), Xphos (0.185 mmol, 16 mol %), and KOAc (2.77 mmol, 2.4 mmol) indioxane, placed in a resealable pressure vessel was degassed throughbubbling nitrogen for 40 min then heated at 110° C. for 4 h. A TLC checkrevealed that all the bromopyridine had been converted to the boronicester. The reaction was allowed to cool to room temperature, and K₃PO₄(2.89 mmol, 2.5 equiv), a solution of 23 (0.1 mmol, 0.87 equiv) indioxanes, an additional 3 mol % of Pd₂dba₃ and H₂O (1 mL) were added tothe reaction. The mixture was degassed for 30 min and heated for 18 h at110° C. The reaction was cooled to room temperature and extracted withEtOAC (3×30 mL). The combined organic layers were dried over MgSO₄,filtered through Celite and the solvent was removed in vacuo. Twopurifications of the residue by flash chromatography through an ISCOcolumn using CHCl₃/MeOH (10:1) provided 60 mg (21%) of 39 as a colorlessoil. ¹H NMR (300 MHz, CDCl₃) δ 1.51-1.71 (m, 5H), 1.90-1.97 (m, 1H),2.36 (br s, 1H), 2.80-2.85 (dd, J=3.8, 5.0 Hz, 1H), 3.61 (s, 1H), 3.81(d, J=2.7 Hz, 1H), 4.66 (br s, 2H), 6.72 (s, 1H), 6.84 (d, J=5.3 Hz,1H), 8.02 (dd, J=2.3, 9.5 Hz, 1H), 8.11 (s, 1H), 8.13 (d, J=5.7 Hz,1H);¹³CNMR (CDCl₃) δ 30.2, 31.4, 40.5, 44.3, 56.5, 62.9, 108.1, 113.9,139.4, 140.6, 143.7, 145.9, 148.5, 157.4, 158.8, 160.6; MS (ESI) m/z285.5 (M+H)⁺.

2-Fluoro-3-(2′-amino-4′-pyridinyl)deschloroepibatidine hydrochloride(40).

Prepared in similar protocol as compound 36 to provide 90% yield of thesalt as a white solid. Mp. 205-208° C. ¹H NMR (300 MHz, CD₃OD) δ1.83-2.28 (m, 5H), 2.46-2.53 (dd, J=3.8, 9.6 Hz, 1H), 3.52-3.57 (dd,J=3.1, 5.5 Hz, 1H), 4.37 (d, J=3.6 Hz, 1H), 4.59 (d, J=2.7 Hz, 1H),7.02-7.05 (dd, J=1.6, 6.1 Hz, 1H), 7.10 (s, 1H) 7.98 (d, J=6.1 Hz, 1H)8.16 (dd, J=2.3, 9.2 Hz, 1H) 8.28 (s, 1H); ¹³CNMR (CD₃OD) δ 26.8, 28.9,37.5, 43.3, 60.5, 64.2, 112.0, 113.8, 137.4, 141.3, 143.2, 148.0, 148.2,158.8, 158.9, 162.1; MS (ESI) m/z 285.7 [(M−HCl)⁺, M=C₁₆H₁₇FN₄.2HCl];Anal. (C₁₆H₁₉Cl₂FN₄) C, H, N.

Example 5 Synthesis of Epibatidine Analogues 41-45

The analogues synthesized in the exemplary procedures discussed underthis section differ from the analogues discussed under Examples 1through 4 in that the fluoro group at the C-2′ position is replaced witha hydrogen.

Syntheses of Analogues 41-43

The synthesis of the deschloroepibatidine analogues 41 to 43 startedwith the Heck cross coupling of7-text-butoxycarbonylazabicyclo[2.2.1]heptene 4 and 3,5-dibromopyridineor 3-bromo-5-iodopyridine in the presence of Pd(OAc)₂, n-Bu₄NCl andpotassium formate, heated in DMF at 100° C. for 48 h to provide7-tert-butoxycarbonyl-2-exo-(3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane,48 in yields of between 40% and 59% (Scheme 10). For analogs 41 and 42,the substituted azabicyclo heptane 48 was subjected to Suzukicross-coupling with the respective boronic acids in the presence ofPd(OAc)₂ and P(o-tolyl)₃ as the catalytic system, Na₂CO₃ as the base,DME as solvent with a catalytic amount of water and was heated at 80° C.for 5 h to furnish the bipyridine derivatives 49 and 50 (Scheme 11). Inthe case of analog 43, the Suzuki cross-coupling of 48 with 4-pyridineboronic acid in the presence of Pd(PPh₃)₄ and K₂CO₃ as base, heated atreflux in toluene (15 mL), ethanol (2 mL) and water (2 mL) for 24 hprovided the desired product 51 in a 55% yield. Removal of the Boc incompounds 49-51 was accomplished using TFA in CH₂Cl₂ to provide theanalogs 41, 42 and 43 which were then converted to the fumarate salts.

Experimental Procedure:

7-tert-butoxycarbonyl-2-exo-(3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane(48).

A solution of 7-tert-butoxycarbonylazabicyclo[2.2.1]heptene (4) (2.16 g,12.9 mmol, 1.0 equiv) in DMF (10 mL), 3,5-dibromopyridine (7.3 g, 25.8mmol, 2.0 equiv), n-Bu₄NCl (900 mg, 3.22 mmol, 25 mol %) and Pd(OAc)₂(145 mg, 0.65 mmol, 5 mol %) was placed in a resealable pressure vessel,degassed through bubbling nitrogen for 40 min and was then heated at 80°C. After 48 h, the mixture was cooled to rt, diluted with EtOAc, andfiltered though Celite into a flask containing a 1:1 solution ofNH₄OH/H₂O (100 mL). The organic product was extracted with CHCl₃ (3×100mL) The combined organic layers were dried over MgSO₄, filtered throughCelite and solvent removed in vacuo. Purification of the residue byflash chromatography through an ISCO column provided 1.82 g (40%) of 48as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 1.45 (br s, 9H), 1.49-1.61(m, 2H), 1.81-1.85 (m, 3H), 1.97-2.04 (m, 1H), 2.86-2.91 (m, 1H), 4.21(s, 1H), 4.39 (br s, 1H), 7.81 (s, 1H), 8.42 (d, J=1.7 Hz, 1H), 8.49 (d,J=2.0 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.2 (3 C), 28.7, 29.6, 40.0, 45.2,55.8, 61.6, 79.7, 120.7, 136.7, 142.8, 147.1, 148.6; MS (ESI) m/z 353.3(M+H)⁺.

General Procedure for the Synthesis of 49 and 50.

To a resealable reaction vessel under nitrogen was added 1.0 equiv of48, Pd(OAc)₂ (0.1 equiv), P(o-tolyl)₃ (0.2 equiv), sodium carbonate (2.0equiv) and the respective pyridinyl boronic acid (1.6 equiv), DME (6 mL)and water (0.7 mL) The mixture was degassed through bubbling nitrogenfor 40 min and heated at 80° C. for 5 h. The mixture was cooled, pouredinto 20 mL of a saturated aqueous solution of NaHCO₃ (20 mL) andextracted with EtOAc (3×30 mL). The combined organic layers were driedover MgSO₄, filtered through Celite and the solvent removed underreduced pressure. The resultant residue was purified by flashchromatography (EtOAc/hexanes).

7-tert-Butoxycarbonyl-2-exo-[3′-(2-chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(49).

The reagents were compound 48 and 2-chloropyridine-4-boronic acid. ¹HNMR (300 MHz, CDCl₃) δ 1.45 (br s, 9H), 1.48-1.69 (m, 2H), 1.87-1.91 (m,3H), 2.05-2.12 (m, 1H), 2.98-3.03 (m, 1H), 4.29 (s, 1H), 4.43 (br s,1H), 4.54 (s, 2 NH), 7.46 (dd, J=1.5, 4.2 Hz, 1H), 7.55 (s, 1H), 7.94(t, J=2.0 Hz, 1H), 8.47 (d, J=5.2 Hz, 1H), 8.58 (d, J=2.0 Hz, 1H), 8.71(d, J=2.2 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.7, 40.5, 45.3,55.9, 61.7, 79.9, 120.3, 122.0, 132.4, 132.5, 141.7, 145.8, 148.5,150.0, 150.2, 152.4, 154.9; MS (ESI) m/z 386.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[3′-(2-flouropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(50).

The reagents were compound 48 and 2-flouropyridine-4-boronic acid. ¹HNMR (300 MHz, CDCl₃) δ 1.44 (br s, 9H), 1.48-1.69 (m, 2H), 1.87-1.93 (m,3H), 2.05-2.12 (dd, J=9.0 Hz, 1H), 2.99-3.03 (m, 1H), 4.29 (s, 1H), 4.43(br s, 1H), 4.54 (s, 2 NH), 7.16 (s, 1H), 7.42-7.44 (dt, J=1.7, 5.2 Hz,1H), 7.95 (t, J=2.0 Hz, 1H), 8.30 (d, J=5.3 Hz, 1H), 8.59 (d, J=2.0 Hz,1H), 8.73 (d, J=2.2 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.7,40.5, 45.3, 56.0, 61.8, 79.9, 107.4, 119.4, 132.5, 141.6, 145.8, 148.2,150.0, 150.9, 154.9, 162.9, 166.0; MS (ESI) m/z 386.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[3′-(pyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(51).

To a resealable reaction pressure vessel under nitrogen was added 48(292 mg, 0.83 mmol, 1.0 equiv), Pd(PPh₃)₄ (48 mg, 0.041 mmol, 5 mol %),potassium carbonate (229 mg, 1.66 mmol, 2.0 equiv), pyridine 4-boronicacid (132 mg, 1.08 mmol, 1.3 equiv), toluene (15 mL), ethanol (2 mL) andwater (2 mL) The mixture was degassed through bubbling nitrogen andheated at 110° C. for 24 h. After cooling to room temperature themixture was poured into 30 mL of H₂O and extracted with EtOAc (3×30 mL)The combined organic layers were dried over MgSO₄, filtered throughCelite and the solvent removed in vacuo. The resultant residue waspurified by flash chromatography using hexanes/isopropanol to furnish159 mg (55%) of 51 as an colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.43(br s, 9H), 1.58-1.66 (m, 2H), 1.87-1.94 (m, 3H), 1.93-2.00 (m, 1H),2.04-2.11 (dd, J=9.0 Hz, 1H), 2.97-3.02 (m, 1 H), 4.29 (s, 1H), 4.43 (brs, 1H), 7.51-7.56 (m, 2H), 7.93 (d, J=1.9 Hz, 1H), 8.56 (d, J=1.9 Hz,1H) 8.69-8.74 (m, 3H); ¹³C NMR (CDCl₃) δ; 28.3 (3 C), 28.8, 29.8, 40.4,45.4, 55.9, 61.8, 79.8, 121.5, 132.5, 133.5, 141.4, 145.3, 145.9, 149.4,150.4, 154.8; MS (ESI) m/z 352.3 (M+H)⁺.

General Procedure for Boc Removal in the Synthesis of Analogues 41-43.

A solution of the Boc protected analog in CH₂Cl₂ (5 mL) and TFA (1 mL)was stirred at rt for between 1 and 3 h. The solvent was removed underreduced pressure and the residual was and treated with a 20 mL solutionof NH₄OH/H₂O (3:1). The organic product was extracted with CHCl₃ (3×30mL), dried over anhydrous sodium sulfate, filtered through Celite andconcentrated in vacuo. Purification of the residual by flashchromatography through an ISCO column provided the amine analogs 41-43in quantitative yields as colorless oils.

2-exo-[3′-(2-Chloropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(41).

¹H NMR (300 MHz, CDCl₃) δ 1.57-1.74 (m, 6H), 1.93-2.00 (dd, J=9.1, 11.2Hz, 1H), 2.85-2.89 (m, 1H), 3.65 (s, 1H), 3.83 (br s 1H), 7.45 (dd,J=1.5, 5.2 Hz, 1H), 7.56 (s, 1H), 8.05 (t, J=2.1 Hz, 1H), 8.47 (d, J=5.2Hz, 1H) 8.62 (d, J=2.0 Hz, 1H), 8.68 (d, J=2.2 Hz, 1H); ¹³C NMR (CDCl₃)δ 30.3, 31.6, 40.4, 45.1, 56.4, 62.8, 120.5, 122.1, 132.3, 133.1, 142.7,145.6, 148.8, 150.2, 152.4; MS (ESI) m/z 286.5 (M+H)⁺.

2-exo-[3′-(2-Fluoropyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(42).

¹H NMR (300 MHz, CDCl₃) δ 1.50-1.75 (m, 6H), 1.82 (br s, 1 H), 1.94-2.01(dd, J=9.0, 11.2 Hz, 1H), 2.85-2.90 (dd, J=3.9, 6.9 Hz, 1H), 3.65 (s,1H), 3.84 (br s 1H), 7.17 (s, 1H), 7.43 (dt, J=1.6, 5.2 Hz, 1H), 8.07(t, J=2.1 Hz, 1H), 8.29 (d, J=5.2 Hz, 1H) 8.63 (d, J=2.0 Hz, 1H), 8.71(d, J=2.2 Hz, 1H); ¹³C NMR (CDCl₃) δ 30.3, 31.5, 40.1, 45.1, 56.4, 62.8,107.0, 119.5, 133.1, 142.7, 145.6, 148.2, 148.4, 151.2, 162.8, 166; MS(ESI) m/z 270.4 (M+H)⁺.

2-exo-[3′-(Pyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane (43).

¹H NMR (300 MHz, CDCl₃) δ 1.50-1.88 (m, 7H), 1.93-2.00 (dd, J=9.0, 11.2Hz, 1H), 2.85-2.90 (dd, J=3.9, 6.9 Hz, 1H), 3.65 (s, 1H), 3.82 (br s1H), 7.53 (d, J=5.6 Hz, 2H), 8.04 (t, J=2.0 Hz, 1H), 8.60-8.71 (m, 4H);¹³C NMR (CDCl₃) δ 30.2, 31.5, 40.4, 45.2, 56.4, 62.8, 121.6, 133.0,133.5, 142.5, 145.6, 149.6, 150.4; MS (ESI) m/z 252.3 (M+H)⁺.

General Procedure for the Preparation of the Fumarates Salts ofAnalogues 41, 42 and 43.

A solution of the amine in ether (2 mL) was treated with a solution offumaric acid (1.2 equivalent) in MeOH. The mixture was left to stand ina refrigerator overnight. Filtration and washing of the filter cake withether, followed by recrystallization from MeOH-ether provided fumaratesalts 52, 53, and 54.2-exo-3′-(2″-Chloro-4″-pyridinyl)deschloroepibatidine fumarate (52).

¹H NMR (500 MHz, METHANOL-d₄) δ 8.85 (d, J=1.95 Hz, 1H), 8.65 (d J=1.85Hz, 1H), 8.48 (d, J=5.35 Hz, 1H), 8.20-8.23 (m, 1H), 7.90-7.93 (m, 1H),7.77 (dd, J=1.66, 5.27 Hz, 1H), 6.69 (s, 2H), 4.61-4.64 (br s, 1H),4.35-4.38 (br s, 1H), 3.53-3.59 (m, 1H), 2.47-2.55 (m, 1H), 2.21-2.21(m, 1H), 2.07-2.11 (m, 1H), 1.98-2.07 (m, 1H), 1.89-1.97 (m, 1H); ¹³CNMR (500 MHz, METHANOL-d₄) δ 27.0, 29.1, 37.8, 44.0, 60.4, 64.0, 122.3,123.7 134.3, 135.1, 136.0, 139.7, 147.4, 150.0, 150.7, 151.5, 153.5,170.5; MS (ESI) m/z 286.5 [(M−fumarate)⁺, M=C₁₆H₁₆ClN₃.C₄H₄O₄]. Anal.(C₂₀H₂₀ClN₃O₄), C, H, N.

2-exo-3′-(2″-Fluoro-4″-pyridinyl)deschloroepibatidine fumarate (53).

Mp. 210-214° C.; ¹H NMR (500 MHz, METHANOL-d₄) δ 8.87 (d, J=1.74 Hz,1H), 8.65 (d, J=1.74 Hz, 1H), 8.33 (d, J=5.23 Hz, 1H), 8.22-8.23 (m,1H), 7.72 (td, J=1.70, 5.32 Hz, 1H), 7.52 (s, 1H), 6.671 (s, 2H), 4.63(br s, 1H), 4.35-4.37 (br s, 1H), 3.55-3.57 (m, 1H), 3.57 (d, J=5.93 Hz,1H), 2.50 (d, J=9.76 Hz, 3H), 2.52 (d, J=9.76 Hz, 3H), 2.21 (s, 6H),1.98-2.16 (m, 17H), 1.87-1.908 (m, 6H); ¹³C (500 MHz, METHANOL-d₄) δ27.3, 29.1, 37.7, 44.0, 60.4, 64.0, 108.6, 121.2, 135.1, 136.0, 139.7,147.3, 149.5, 149.6, 150.6, 170.5; MS (ESI) m/z 270.2 [M−fumarate)⁺,M=C₁₆H₁₆FN₃.C₄H₄O₄]. Anal. (C₂₀H₂₀FN₃O₄.0.5H₂O), C, H, N.

2-exo-3′-(4″-Pyridinyl)deschloroepibatidine fumarate (54).

¹H NMR (500 MHz, METHANOL-d₄) δ 8.85 (d, J=1.74 Hz, 1H), 8.66-8.67 (m,2H), 8.64 (d, J=2.1 Hz, 1H), 8.21-8.22 (m, 1H), 7.83-7.84 (m, 2H), 6.69(s, 2H), 4.63 (d, J=3.83 Hz, 1H), 4.37 (br s, 1H), 3.57 (dd, J=6.10,9.59 Hz, 1H), 2.52 (dd, J=9.59, 13.42 Hz, 1H), 2.15-2.26 (m, 1H),1.97-2.15 (m, 4H), 1.82-1.97 (m, 1H); ¹³C NMR (500 MHz, METHANOL-d₄) δ27.03, 29.07, 37.72, 44.01, 60.44, 64.00, 123.57, 135.07, 135.33,135.90, 139.60, 147.17, 147.30, 150.14, 151.06, 170.06; MS (ESI) m/z252.3 [(M−fumarate)⁺, M=C₁₆H₁₇N₃.C₄H₄O₄]. Anal. (C₂₀H₂₁N₃O₄), C, H, N.

Synthesis of Analogue 44 and 45.

The synthesis of the hydrochloride salt of 44 was accomplished asillustrated in Scheme 12. The bromo compound 48 was subjected to aborylation reaction through cross-coupling reaction withbis(pinacolata)diborane in the presence of potassium acetate as base andPdCl₂(dppf) as the catalyst and heated in dioxane at 110° C. overnightto provide the boronic ester 55 in a 84% yield upon purification. Theboronic ester was then subjected to a Suzuki-Miyaura cross-couplingreaction with 2-amino-4-bromopyridine (37) to provide compound 56 in a74% yield. Removal of the Boc protecting group was accomplished bystirring 56 in TFA/CH₂Cl₂ at room temperature for 1 h. The amine 44obtained was converted to a hydrochloride salt 57 using a solution ofHCl in diethyl ether.

Similarly, the synthesis of the 2-methoxypryridine substituted analogue45, as shown in Scheme 13 below, was accomplished through across-coupling of 4-bromo-2-methoxypyridine (34) with the boronic ester55 in the presence of Pd(PPh₃), K₂CO₃, dioxane and water heated at 110°C. for 24 h to provide compound 58 in a 63% yield. Removal of the Boc bystirring 58 in TFA at room temperature provided the amine 45 that wasthen converted to its fumarate salt 59.

Experimental Procedure:

7-tert-Butoxycarbonyl-2-exo-[5′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3′-pyridnyl]-7-azabicyclo[2.2.1]heptane(55).

To a resealable reaction pressure vessel under nitrogen was added asolution of 48(7-tert-butoxycarbonyl-2-exo-(3′-bromo-5′-pyridinyl)-7-azabicyclo[2.2.1]heptane)(209 mg, 0.5904 mmol, 1.0 equiv), PdCl₂(dppf) (22 mg, 0.0295 mmol, 5 mol%), and KOAC (180 mg, 1.83 mmol, 3.0 equiv) in dioxane (10 mL) Themixture was degassed through bubbling nitrogen for 40 min then heated at110° C. for 24 h. After cooling to room temperature the reaction wasdiluted in EtOAc and filtered through a plug of Celite and anhydroussodium sulfate. The solvent was removed in vacuo and the residue waspurified by flash chromatography (EtAOc) to provide 199 mg (84%) of 55as a brownish oil.

7-tert-Butoxycarbonyl-2-exo-[3′-(2-aminopyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(56).

To a resealable reaction pressure vessel under nitrogen was added 1.0equiv of 55 (265 mg, 0.662 mmol), Pd(PPh₃)₄ (38 mg, 0.033 mmol, 5 mol%), K₂CO₃ (184 mg, 1.324 mmol, 2.0 equiv), 2-amino-4-bromopyridine (137mg, 0.794 mmol, 1.2 equiv), dioxane (12 mL) and water (1 mL). Themixture was degassed through bubbling nitrogen for 40 min and heated at110° C. for 20 h. After cooling to room temperature, water (10 mL) wasadded and the organic product was extracted using EtOAc (3×30 mL) Thecombined organic layers were dried over MgSO₄, filtered through Celiteand the solvent removed in vacuo. The residual was purified by flashchromatography to provide 180 mg (74%) of 56 as colorless oil. ¹H NMR(300 MHz, CDCl₃) δ 1.43 (br s, 9H), 1.53-1.66 (m, 2H), 1.80-1.91 (m,3H), 2.01-2.08 (m, 1H), 2.94-2.98 (m, 1H), 4.27 (s, 1H), 4.41 (br s,1H), 4.76 (s, 2 NH), 6.70 (s, 1H), 6.85 (d, J=4.3 Hz, 1H), 7.85 (s, 1H),8.13 (d, J=5.3 Hz, 1H), 8.52 (d, J=1.7 Hz, 1H), 8.67 (d, J=1.2 Hz, 1H);¹³C NMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.8, 40.4, 45.5, 55.9, 61.8, 79.8,106.2, 112.3, 132.5, 134.2, 141.2, 145.9, 147.1, 148.8, 149.1, 154.9,159.1; MS (ESI) m/z 367.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[3′-(2-aminopyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(58). To a resealable reaction pressure vessel under nitrogen was added1.0 equiv of 55 (266 mg, 0.665 mmol), Pd(PPh₃)₄ (38 mg, 0.033 mmol, 5mol %), K₂CO₃ (184 mg, 1.33 mmol, 2.0 equiv), 2-methoxy-4-bromopyridine(137 mg, 0.732 mmol, 1.1 equiv), dioxane (20 mL) and water (2 mL). Themixture was degassed through bubbling nitrogen for 40 min and heated at110° C. overnight. After cooling to room temperature, water (20 mL) wasadded and the organic product was extracted using EtOAc (3×30 mL) Thecombined organic layers were dried over MgSO₄, filtered through Celiteand the solvent removed in vacuo. The residual was purified by flashchromatography to provide 160 mg (63%) of 58 as colorless oil. ¹H NMR(300 MHz, CDCl₃) δ 1.42 (br s, 9H), 1.49-1.63 (m, 2H), 1.86-1.98 (m,3H), 2.00-2.07 (m, 1H), 2.96-3.01 (m, 1H), 3.92 (s, 3H), 4.30 (s, 1H),4.42 (br s, 1H), 6.81 (dd, J=5.7, 2.4 Hz, 1H), 7.25 (d, J=2.2 Hz, 1H),8.22 (t, J=1.9 Hz, 1H), 8.53 (d, J=5.7 Hz, 1H), 8.56 (d, J=2.0 Hz, 1H),9.00 (d, J=2.0 Hz, 1H); ¹³C NMR (CDCl₃) δ 28.3 (3 C), 28.8, 29.9, 40.2,45.8, 55.9, 61.8, 79.7, 107.2, 108.6, 132.9, 134.7, 140.9, 146.2, 149.1,151.1, 155.0, 156.7 166.5; MS (ESI) m/z 382.7 (M+H)⁺.

General Procedure for Boc Removal in the Synthesis of Analogues 56 and58.

A solution of the Boc protected analog in CH₂Cl₂ (5 mL) and TFA (1 mL)was stirred at rt for between 1 and 3 h. The solvent was removed underreduced pressure and the residual was and treated with a 20 mL solutionof NH₄OH/H₂O (3:1). The organic product was extracted with CHCl₃ (3×30mL), dried over anhydrous sodium sulfate, filtered through Celite andconcentrated in vacuo. Purification of the residual by flashchromatography through an ISCO column provided the amine analogues 44and 45 in good yields as colorless oils.

2-exo-[3′-(2-Aminopyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(44). ¹H NMR (300 MHz, CDCl₃) δ 1.50-1.76 (m, 6H), 1.86 (br s, 1H)1.92-1.99 (dd, J=9.0, 11.2 Hz, 1H), 2.84-2.88 (dd, J=3.9, 6.9 Hz, 1H),3.64 (s, 1H), 3.83 (br s 1H), 4.69 (br s, 2H) 6.70 (s, 1H), 6.85 (dd,J=1.1, 5.3 Hz, 1H), 7.85 (d, J=1.7 Hz, 1H), 8.13 (d, J=5.3 Hz, 1H), 8.55(d, J=1.8 Hz, 1H), 8.65 (d, J=2.0 Hz, 1H); ¹³C NMR (CDCl₃) δ 30.2, 31.5,40.4, 45.2, 56.5, 62.8, 106.2, 112.5, 132.9, 134.1, 142.2, 145.6, 147.4,148.9, 149.3, 159.1; MS (ESI) m/z 267.1 (M+H)⁺.

2-exo-[3′-(2-Methoxypyridin-4-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(45). ¹H NMR (300 MHz, CDCl₃) δ 1.50-1.76 (m, 6H), 1.86 (br s, 1H)1.92-1.99 (dd, J=9.0, 11.2 Hz, 1H), 2.84-2.88 (dd, J=3.9, 6.9 Hz, 1H),3.64 (s, 1H), 3.83 (br s 1H), 4.69 (br s, 2H) 6.70 (s, 1H), 6.85 (dd,J=1.1, 5.3 Hz, 1H), 7.85 (d, J=1.7 Hz, 1H), 8.13 (d, J=5.3 Hz, 1H), 8.55(d, J=1.8 Hz, 1H), 8.65 (d, J=2.0 Hz, 1H); ¹³C NMR (CDCl₃) δ 30.0, 31.3,40.2, 45.5, 55.2, 56.5, 62.8, 107.3, 108.4, 133.1, 134.6, 141.8, 145.8,149.4, 151.2, 156.8, 166.4; MS (ESI) m/z 282.5 (M+H)⁺.

2-exo-3′-(2″-Amino-4″-pyridinyl)deschloroepibatidine Hydrochloride (57).Prepared using HCl in diethyl ether and recrystallized from MeOH/diethylether to provide 66% yield of the salt as a purplish solid. Mp. 209-214°C. ¹H NMR (300 MHz, CD₃OD) δ 1.90-2.0 (m, 4H), 2.10-2.34 (m, 1H),2.52-2.60 (dd, J=9.0, 11.2 Hz, 1H), 3.64-3.69 (dd, J=3.9, 6.9 Hz, 1H),4.42 (s, 1H), 4.70 (br s 1H), 7.38 (dd, J=1.6, 6.8 Hz, 1H), 7.49 (s,1H), 8.01 (d, J=6.7 Hz, 1H), 8.49 (s, 1H), 8.82 (s, 1H), 8.96 (s, 1H);¹³CNMR (CD₃OD) δ 26.8, 28.9, 37.4, 43.9, 60.5, 64.0, 112.5, 112.7,137.3, 137.4, 140.3, 145.9, 149.9, 153.2; MS (ESI) m/z 267.2 [(M−HCl)⁺,M=C₁₆H₁₈N₄.2HCl]; Anal. (C₁₆H₂₀Cl₂N₄.1.5 H₂O), C, H, N.

2-exo-(2″-Methoxy-4″-pyridinyl)deschloroepibatidine fumarate (59). Mp.160-164° C.; ¹H NMR (300 MHz, METHANOL-d₄) δ 8.99 (d, J=1.74 Hz, 1H)8.60 (d, J=1.71 Hz, 1H), 8.51 (d, J=5.85 Hz, 1H), 7.52 (d, J=1.8 Hz,1H), 7.04 (dd, J=2.4, 5.82 Hz, 1H), 6.68 (s, 1H), 4.60 (d, J=2.0 Hz,1H), 4.37 (br s, 1H), 3.98 (s, 3H), 3.57 (dd, J=3.3, 9.3 Hz, 1H),2.45-2.53 (m, 1H), 1.86-2.26 (m, 6H); ¹³C NMR (300 MHz, METHANOL-d₄) δ26.99, 28.84, 37.33, 43.91, 56.32, 60.33, 64.15, 109.52, 110.58, 134.72,135.87, 138.97, 147.41, 149.72, 152.18, 157.20, 170.89; MS (ESI) m/z282.4 [(M−fumarate)⁺, M=C₁₆H₁₆FN₃.C₄H₄O₄]. Anal. (C₂₀H₂₀FN₃O₄.0.5H₂O),C, H, N.

Example 6 Synthesis of EpibatidineAnalogues—2′-Pyrimidinedeschloroepibatidine and 2′-Pyridazine Analogues.

The exemplary procedures discussed below outline the routes to thesynthesis of the pyrimidine analogues 60, 61 and 62.

The synthesis of all the analogues started with the Heck cross-couplingof olefin 4 with either 3,5-dibromopyridine or 2-amino-5-iodopyridine inthe presence of Pd(OAc)₂, n-Bu₄NCl and potassium formate, heated in DMFat 100° C. for 2 or 4 days to provide 6 or 48 respectively. Brominationof 6 was accomplished through the use of bromine in the presence ofglacial acetic acid to provide 7 (Scheme 14).

The synthesis of the pyrimidine analogues 60 and 61 commenced with thecross-coupling of pyrimidine boronic acid with either of the bromointermediates 7 or 48. Suzuki cross-coupling of either 7 or 48 withpyrimidine boronic acid in the presence of Pd(PPh₃)₄, Na₂CO₃, DME andwater, heated at 100° C. for 24 h provided the pyrimidine substitutedcompounds 66 or 69 respectively (see Schemes 15 and 17). For thesynthesis of the 2′-fluorinated analogue 60, as illustrated in Scheme15, the diazotization of the amino functional group in compound 66 using70% HF in pyridine provided the desired 2′-fluorinated amine 60 and thiswas subsequently converted to the fumarate salt 67. On the other hand,diazotization of 66 using HCl and NaNO₂ provided the 2′-chlorinatedanalogue 61, which was subsequently converted to the Fumarate salt 68 asshown in Scheme 16. The cross-coupled product 69 as outlined in Scheme17 was treated with TFA for the removal of the Boc protecting group toprovide analogue 62 that was converted to the fumarate salt 70.

Experimental Procedure:

7-tert-Butoxycarbonyl-2-exo-[2′-amino-3′-(pyrimidin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(66).

To a resealable reaction pressure vessel under nitrogen was added 7(827, 2.25 mmol, 1.0 equiv), Pd(PPh₃)₄ (130, 0.112 mmol, 5 mol %),Na₂CO₃ (476 mg, 4.49 mmol, 2.0 equiv), pyrimidine boronic acid (362 mg,2.92 mmol, 1.3 equiv), DME (12 mL), and water (1.5 mL) The mixture wasdegassed through bubbling nitrogen for 40 min and heated at 100° C. for24 h. After cooling to room temperature the mixture was poured into 30mL of H₂O and extracted with CHCl₃ (3×40 mL) The combined organic layerswere dried over MgSO₄, filtered through Celite and the solvent removedin vacuo. The resultant residue was purified by flash chromatographyusing hexanes/EtOAc to furnish 585 mg (71%) of 66 as yellowish oil. ¹HNMR (300 MHz, CDCl₃) δ 1.44 (br s, 9H), 1.49-1.62 (m, 3H), 1.81-1.85 (m,3H), 1.95-2.02 (m, 1H), 2.80-2.84 (dd, J=9.0 Hz, 1H), 4.16 (s, 1H), 4.35(br s, 1H), 7.37 (d, J=1.7 Hz, 1H), 8.01 (d, J=2.0 Hz, 1H) 8.86 (s, 2H),9.18 (s, 1H); ¹³C NMR (CDCl₃) δ; 28.2 (3 C), 28.7, 29.6, 40.2, 44.7,55.8, 62.1, 79.5, 114.3, 132.1, 132.4, 137.0, 147.5, 154.6, 154.9,156.6, 157.5; MS (ESI) m/z 368.4 (M+H)⁺.

2-exo-[2′-Fluoro-3′-(pyrimidin-3-yl)-5′-pyridinyl]-7-azabicyclo[2.2.1]heptane(60).

A solution of 66 (353 mg, 0.961 mmol, 1.0 equiv) in 70% HF-pyridine (3mL) in a plastic reaction vessel was stirred at 0° C. for 30 min. Sodiumnitrite (663 mg, 9.61 mmol, 10 equiv) was then added in small portionsand the mixture stirred at room temperature for 1 h. The mixture wasthen poured into a solution of 1:1 NH₄OH/H₂O (40 mL) and extracted withCHCl₃ (3×50 mL). The combined organic layers were dried over MgSO₄,filtered through Celite and concentrated in vacuo. The residue waspurified by flash chromatography using CHCl₃/MeOH (10:1) to provide 126mg (48%) of 60 as a colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.55-1.81(m, 6H), 1.92-1.99 (m, 1H), 2.83-2.87 (dd, J=3.8, 5.0 Hz, 1H), 4.16 (s,1H), 3.61 (br s, 1H), 3.83 (s, 1H), 8.14-8.20 (s, 2H), 8.98 (s, 2H),9.24 (s, 1H); ¹³C NMR (CDCl₃) δ 30.4, 31.5, 40.7, 44.3, 56.3, 62.9,116.6, 128.5, 139.5, 141.6, 146.7, 156.2, 158.0, 160.5; MS (ESI) m/z271.6 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[2′-chloro-3′-(pyrimidin-5-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(61).

To a solution of 66 (390 mg, 1.06 mmol, 1.0 equiv) in HCl (10 mL) at 0°C. was added slowly NaNO₂ (1.47 g, 21.23 mmol, 20 equiv). The mixturewas stirred at 0° C. for 1 h then at rt for an additional 3 h. Thereaction was quenched with 20 mL NH₄OH/H₂O (3:1) solution and extractedwith CHCl₃ (3×30 mL) The combined organic layers were dried over MgSO₄,filtered through Celite and concentrated in vacuo. The residue obtainedwas purified by flash chromatography through an ISCO column usingCHCl₃/MeOH (10:1) to provide 213 mg (70%) of the 61 as a colorless thickoil. ¹H NMR (300 MHz, CDCl₃) δ 1.54-1.74 (m, 6H), 1.92-1.99 (m, 1H),2.81-2.85 (dd, J=3.8, 5.0 Hz, 1H), 3.61 (s, 1H), 3.82 (br s, 1H), 7.93(d, J=2.3 Hz, 1H) 8.40 (d, J=2.3 Hz, 1H), 8.88 (s, 2H), 9.26 (s, 1H);¹³C NMR (CDCl₃) δ 30.4, 31.5, 40.5, 44.3, 56.3, 62.8, 123.8, 129.6,131.8, 142.4, 147.0, 149.1, 156.7, 158.0; MS (ESI) m/z 287.3 (M+H)⁺.

7-tert-Butoxycarbonyl-2-exo-[3′-(pyrimidin-5-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane(69).

To a resealable reaction pressure vessel under nitrogen was added 48(316 mg, 0.895 mmol, 1.0 equiv), Pd(PPh₃)₄ (52 mg, 0.045 mmol, 0.1equiv), Na₂CO₃ (190 mg, 1.79 mmol, 2.0 equiv), pyrimidine boronic acid(144 mg, 1.16 mmol, 1.3 equiv), DME (16 mL), and water (1.5 mL). Themixture was degassed through bubbling nitrogen for 40 min and heated at100° C. for 24 h. After cooling to room temperature the mixture waspoured into 30 mL of H₂O and extracted with CHCl₃ (3×40 mL) The combinedorganic layers were dried over MgSO₄, filtered through Celite and thesolvent removed in vacuo. The resultant residue was purified by flashchromatography using hexanes/EtOAc to furnish 285 mg (90%) of 69 as acolorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.44 (br s, 9H), 1.58-1.69 (m,3H), 1.87-1.94 (m, 3H), 2.05-2.12 (m, 1H), 2.99-3.04 (dd, J=9.0 Hz, 1H),4.30 (s, 1H), 4.43 (br s, 1H), 7.91 (t, J=1.9 Hz, 1H), 8.61 (d, J=1.7Hz, 1H), 8.70 (d, J=2.0 Hz, 1H) 8.98 (s, 2H), 9.27 (s, 1H); ¹³C NMR(CDCl₃) δ; 28.4 (3 C), 29.0, 29.8, 40.6, 45.5, 56.2, 61.9, 80.1, 130.1,131.7, 132.7, 141.9, 145.9, 149.7, 155.2, 158.2; MS (ESI) m/z 353.5(M+H)⁺.

Procedure for Boc Removal in the Synthesis of Analogue 62.

A solution of the Boc protected analogue 69 in CH₂Cl₂ (5 mL) and TFA (1mL) was stirred at rt for 1 h. The solvent was removed under reducedpressure and the residual was and treated with a 20 mL aqueous solutionof NH₄OH/H₂O (3:1). The organic product was extracted with CHCl₃ (3×30mL). The combined organic layers were dried over anhydrous sodiumsulfate, filtered through Celite and concentrated in vacuo. Purificationof the residual by flash chromatography through an ISCO column providedthe analogue 62 in good yields as a colorless oil.

2-exo-[3′-(Pyrimidin-5-yl)-5′-pyridnyl]-7-azabicyclo[2.2.1]heptane (62).

¹H NMR (300 MHz, CDCl₃) δ 1.57-1.78 (m, 7H), 1.94-2.01 (dd, J=9.0, 11.2Hz, 1H), 2.87-2.91 (dd, J=3.9, 6.9 Hz, 1H), 3.66 (s, 1H), 3.82 (br s1H), 8.06 (t, J=2.1 Hz, 1H), 8.65 (d, J=2.0 Hz, 1H), 8.67 (d, J=2.0 Hz,1H), 8.99 (s, 2H) 9.25 (s, 1H); ¹³C NMR (CDCl₃) δ 30.3, 31.5, 40.4,45.1, 56.4, 62.8, 129.8, 131.7, 133.0, 142.8, 145.4, 149.7, 154.9,157.9; MS (ESI) m/z 253.3 (M+H)⁺.

General Procedure for the Fumarate Salt Formation (Compounds 67, 68 and70)

A solution of the respective amine (60, 61 or 62) in chloroform (2 mL)was treated with a solution of fumaric acid (1.2 equivalents) in MeOH(0.65M). The mixture was allowed to stand in refrigerator overnight.Filtration and washing of the filter cake with ether, followed byrecrystallization from MeOH-ether provided the desired fumarates aswhite solids.

2-exo-2′-Fluoro-3′-(pyrimidin-5-yl)deschloroepibatidine fumarate (67).

Mp. 160-163° C.; ¹H NMR (500 MHz, METHANOL-d₄) δ 9.22 (s, 1H), 9.10 (s,2H), 8.25-8.32 (m, 1H), 8.21 (dd, J=2.66, 9.20 Hz, 1H), 6.66 (s, 2H),4.58 (d, J=3.68 Hz, 1H), 4.32-4.39 (br s, 1H), 3.53 (m, 1H), 2.48 (dd,J=2.50, 9.81 Hz, 1H), 2.14-2.24 (m, 1H), 1.99-2.14 (m, 3H), 1.85-1.96(m, 1H); ¹³C NMR (500 MHz, METHANOL-d₄) δ 27.0, 28.95, 37.58, 43.41,60.18, 63.83, 133.15, 136.10, 138.88, 140.18, 150.11, 158.27, 158.96,171.15; MS (ESI) m/z 287.3 [(M−fumarate)⁺, M=C₁₅H₁₅FN₄.C₄H₄O₄]. Anal.(C₁₉H₁₉FN₄O₄.1.25H₂O), C, H, N.

2-exo-2′-Chloro-3′-(pyrimidin-5-yl)deschloroepibatidine fumarate (68).

Mp. 199-203° C.; ¹H NMR (300 MHz, METHANOL-d₄) δ 9.23 (s, 1H), 8.98 (s,2H), 8.47 (d, J=2.13 Hz, 1H), 7.98 (d, J=2.13 Hz, 1H), 6.63 (s, 2H),4.57 (d, J=2.2 Hz, 1H), 4.33 (br s, 1H), 3.45-3.54 (m, 1H), 2.43-2.51(dd, J=3.7, 9.70 Hz, 1H), 1.84-2.18 (m, 5H); ¹³C NMR (300 MHz,METHANOL-d₄) δ 27.0, 28.95, 37.58, 43.41, 60.18, 63.83, 133.15, 136.10,138.88, 140.18, 150.11, 158.27, 158.96, 171.15; MS (ESI) m/z 287.3[(M−fumarate)⁺, M=C₁₅H₁₅ClN₄.C₄H₄O₄]. Anal. (C₁₉H₁₉ClN₄O₄.0.25H₂O), C,H, N.

2-exo-3′-(Pyrimidin-5-yl)deschloroepibatidine fumarate (70).

Mp. 172-176° C.; ¹H NMR (500 MHz, METHANOL-d₄) δ 9.22 (s, 1H), 9.17-9.19(m, 2H), 8.84 (d, J=2.04 Hz, 1H), 8.65 (d, J=2.86 Hz, 1H), 8.20-8.22 (m,1H), 6.64 (s, 2H), 4.62 (d, J=3.68 Hz, 1H), 4.36 (br s, 1H), 3.55-3.57(dd, J=5.72, 6.13 Hz, 1H), 2.43-2.52 (dd, J=3.7, 9.40 Hz, 1H), 2.16-2.25(m, 1H), 1.98-2.15 (m, 3H), 1.87-1.98 (m, 1H); ¹³C NMR (500 MHz,METHANOL-d₄) δ 27.08, 29.06, 37.75, 44.03, 60.39, 63.98, 132.02, 135.03,136.21, 139.74, 147.16, 150.01, 156.67, 159.02, 171.11; MS (ESI) m/z253.3 [(M−fumarate)⁺, M=C₁₅H₁₆N₄.C₄H₄O₄]. Anal. (C₁₉H₂₀N₄O₄.0.75H₂O), C,H, N.

Example 7 Synthesis of 2′-Fluoro-3′-(substituted thiophenyl) EpibatidineAnalogues.

Synthesis of Analogue 71a

The synthesis of the thiophenyl substituted analogues commenced with theHeck cross coupling of 7-tert-butoxycarbonylazabicyclo[2.2.1]heptene 4and 2-amino-5-iodopyridine, 5, in the presence of Pd(OAc)₂, n-Bu₄NCl andpotassium formate, heated in DMF at 100° C. for 4 days intermediate 6,which was subsequently subjected to a bromination reaction as discussedin other examples above to provide bromo compound 7. Suzukicross-coupling with the respective thiophenyl boronic acid in thepresence of Pd(PPh₃)₄ as the catalytic system, Na₂CO₃ as the base, DMFas solvent and a catalytic amount of water, heated at 80° C. for 5 h,furnished cross-coupled product 74 as shown in Scheme 18 below.Diazotization reaction in the presence of HF-pyridine provided analogue71a in a modest yield.

Example 8

Radioligand binding and pharmacology for certain compounds of thepresent invention. [³H]Epibatidine Binding Assay. The [³H]Epibatidinebinding assay is used to determine the affinity (K_(i)) of the testcompound for heteromeric nAChRs containing alpha and beta subunits. Thealpha4 beta2 subtype is the predominant nAChR present in brain tissueused in this assay. [¹²⁵I]Iodo-MLA is a radioligand that is selectivefor homomeric nAChRs containing the alpha7 subunit. Thus, this assay isused to determine the affinity (K_(i)) of the test compound for thisnAChR and results used to calculate the selectivity of the compounds forhetero- and homomeric nAChRs.

Adult male rat cerebral cortices (Pelfreeze Biological, Rogers, Ark.)were homogenized in 39 volumes of ice-cold 50 mM Tris buffer (pH 7.4 at4° C.) containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, and 1 mM MgCl₂ andsedimented at 37,000 g for 10 min at 4° C. The supernatant wasdiscarded, the pellet resuspended in the original volume of buffer, andthe wash procedure repeated twice more. After the last centrifugation,the pellet was resuspended in 1/10 its original homogenization volumeand stored at −80° C. until needed. In a final volume of 0.5 mL, eachassay tube contained 3 mg wet weight male rat cerebral cortex homogenate(added last), 0.5 nM [³H]epibatidine (NEN Life Science Products,Wilmington, Del.) and one of 10-12 different concentrations of testcompound dissolved in buffer (pH 7.4 at room temperature) containing 10%DMSO resulting in a final DMSO concentration of 1%. Total andnonspecific bindings were determined in the presence of vehicle and 300μM (−)-nicotine, respectively. After a 4-h incubation period at roomtemperature, the samples were vacuum-filtered over GF/B filter paperspresoaked in 0.03% polyethylenimine using a Brandel 48-well harvesterand washed with 6 mL of ice-cold buffer. The amount of radioactivitytrapped on the filter was determined by standard liquid scintillationtechniques in a TriCarb 2200 scintillation counter (Packard Instruments,Meriden, Conn.) at approximately 50% efficiency. The binding data werefit using the nonlinear regression analysis routines in Prism (Graphpad,San Diego, Calif.). The K_(i) values for the test compounds werecalculated from their respective IC₅₀ values using the Cheng-Prusoffequation.

[¹²⁵I]Iodo-MLA Binding Assay. Adult male rat cerebral cortices(Pel-Freez Biologicals, Rogers, Ark.) were homogenized (polytron) in 39volumes of ice-cold 50 mM Tris buffer (assay buffer; pH 7.4 at 4° C.)containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, and 1 mM MgCl₂. Thehomogenate was centrifuged at 35,000 g for 10 min at 4° C. and thesupernatant discarded. The pellet was resuspended in the original volumeof buffer and the wash procedure repeated twice more. After the lastcentrifugation step, the pellet was resuspended in one-tenth theoriginal homogenization volume and stored at −80° C. until needed.Triplicate samples were run in 1.4-mL polypropylene tubes (MatrixTechnologies Corporation, Hudson, N.H.). Briefly, in a final volume of0.5 mL, each assay sample contained 3 mg wet weight rat cerebral cortex(added last), 40-50 pM [¹²⁵I]MLA and 50 nM final concentration of testcompound dissolved in buffer containing 10% DMSO, giving a final DMSOconcentration of 1%. Total and nonspecific binding were determined inthe presence of vehicle and 300 μM (−)-nicotine, respectively. After a2-h incubation period on ice, the samples were vacuum-filtered using aMultimate 96-well harvester (Packard Instruments, Meriden, Conn.) ontoGF/B filters presoaked for at least 30 min in assay buffer containing0.15% bovine serum albumin. Each well was then washed with approximately3.0 mL of ice-cold buffer. The filter plates were dried, and 30 μL ofMicroscint20 (Packard) was added to each well. The amount of radioligandremaining on each filter was determined using a TopCount 12-detector(Packard) microplate scintillation counter at approximately 70%efficiency.

Tail-flick Test. Antinociception was assessed by the tail-flick methodof F. E. D'Amour and D. L. Smith (J. Pharmacol. Exp. Ther. 1941, 72,74-79). A control response (2-4 sec) was determined for each mousebefore treatment, and a test latency was determined after drugadministration. In order to minimize tissue damage, a maximum latency of10 sec was imposed. Antinociceptive response was calculated as percentmaximum possible effect (% MPE), where %MPE=[(test-control)/(10-control)]×100. Groups of eight to twelve animalswere used for each dose and for each treatment. The mice were tested 5min after s.c. injections of epibatidine analogues for the dose-responseevaluation. Eight to twelve mice were treated per dose and a minimum offour doses were performed for dose-response curve determination.

Hot-plate Test. Mice were placed into a 10 cm wide glass cylinder on ahot plate (Thermojust Apparatus) maintained at 55.0° C. Two controllatencies at least 10 mM apart were determined for each mouse. Thenormal latency (reaction time) was 8 to 12 sec. Antinociceptive responsewas calculated as percent maximum possible effect (% MPE), where %MPE=[(test-control)/40-control)×100]. The reaction time was scored whenthe animal jumped or licked its paws. Eight mice per dose were injecteds.c. with epibatidine analogues and tested 5 min thereafter in order toestablish a dose-response curve.

Locomotor Activity. Mice were placed into individual Omnitech photocellactivity cages (28×16.5 cm) 5 min after s.c. administration of either0.9% saline or epibatidine analogues. Interruptions of the photocellbeams (two banks of eight cells each) were then recorded for the next 10min. Data were expressed as number of photocell interruptions.

Body Temperature. Rectal temperature was measured by a thermistor probe(inserted 24 mm) and digital thermometer (Yellow Springs Instrument Co.,Yellow Springs, Ohio). Readings were taken just before and 30 min atdifferent times after the s.c. injection of either saline or epibatidineanalogues. The difference in rectal temperature before and aftertreatment was calculated for each mouse. The ambient temperature of thelaboratory varied from 21-24° C. from day to day.

Table 6 provides data for a number of compounds of the invention thatwere tested according to the assays described above. The nicotineacetylcholine receptor (nAChR) binding affinities and activities innAChR animal assays of several compounds that are a part of thisapplication were compared to varenicline (Chantix®), a drug on themarket for helping smokers quit smoking Varenicline aided depressiveaffect in depressed smokers and also showed activity in animal models ofdepression. Varenicline also shows reduction of ethanol consumption andseeking in rat tests. All of the compounds like varenicline have veryhigh affinity for nAChR as judged by inhibition of [³H]epibatidinebinding. The K_(i) values ranged from 0.04 nM to 1.18 nM compared to0.12 nM for varenicline. Like varenicline, all the compounds except onewere functional antagonists in the tail-flick test. In addition, likevarenicline, the compounds showed activity in one or more of thefunctional agonist tests and thus are partial agonists.

TABLE 6 Radioligand Binding and Pharmacology Data for2′-Fluoro-3′-(substituted pyridine) Deschloroepibatidine Analogs

αβ [³H] Epibat- α₇ [¹²⁵I] mg/kg idine iodoMLA ED₅₀ (K_(i), nM) (K_(i),nM) ED₅₀ ED₅₀ ED₅₀ Spon- AD₅₀ (μg/kg) (hill (hill Tail Hot Hypo- taneousTail Hot slope) slope) Flick Plate thermia Activity Flick PlateComparative compounds Nicotine 1.50 ± 0.30 1.3  0.65  1.0  0.5 (0.5-1.8) (0.25-0.85) (0.6-2.1) (0.15-0.78) (−)-epibatidine 0.018 ±0.001 0.006 0.004 0.004 0.001 (0.001-0.01)  (0.001-0.008) (0.002-0.008)(0.0005-0.005)  varenicline 0.12 ± 0.02 32.5 ± 1.3  11% @ 10 10% @ 102.8 2.1   0.2 470 Inventive Compounds R₁

 0.35 ± 0.038 5500 ± 1420 4.9  (3.6-6.7) 5   (3.7-6.7) 3.7  (2.9-4.5)0.69  (0.4-12.8)  3 (0.5-24)  10% @ 1000

0.049 ± 0.02 4850 ± 1800 3.6  (2.7-4.7) 3.27 (2.1-5.3) 0.68 (0.52-1.1) 0.38 (0.13-1.1)  1% @ 100  1% @ 100

0.063 ± 0.08  6600 ± 731  10% @ 10 27% @ 10 3.11 (1.5-5.1) 1.58(0.5-4.4)  9  (2-38) 2001   (297-3610)

 0.25 ± 0.033 1470 ± 203   5% @ 10 8% @ 10 2.8    (2-3.8) 1.84 (0.5-6.3)30  (3-35) 50% @ 10

 0.13 ± 0.027 524 ± 110 4.22   (3-5.3) 1.72 (0.9-3.4) 0.77 (0.51-1.2) 0.53 (0.19-1.1)  21  (3-125)  0% @ 100

0.12 ± 0.03 9700 ± 2400 13% @ 10 40% @ 10 1.69 (1.1-2.6) 0.38 (0.2-2.7)12  (10-172) 290  (19-991)

0.067 ± 0.01  7300 ± 150   5% @ 10 18% @ 10 1.58 (0.97-2.1)  0.17(0.08-1.5)   4 (0.1-70)  117  (110-1100)

1.18 ± 0.14 >10,000 11% @ 10 19% @ 10 2.74 (1.89-3.5)  1.01 (0.27-3.7) 320   (45-3262) 1370   (180-1430)

 0.13 ± 0.005 719 ± 101 11% @ 10 12% @ 10 1.87 (0.1-3.5) 0.61(0.04-9.1)   9 (0.4-19)  10% @ 10,000

 0.04 ± 0.012 7900 ± 1080

Table 7 provides some additional data for additional compounds of theinvention wherein R₁ is pyrimidine and where the X substituent on thepyridine ring is varied. As with the compounds of Table 6, thesecompounds were tested according to the assays described above.

TABLE 7 Radioligand binding and antinociception profile data for3′-(pyrimidine)epibatidine analogs

αβ [³H] Epibat- α₇ [¹²⁵I] mg/kg idine iodoMLA ED₅₀ (K_(i), nM) (K_(i),nM) ED₅₀ ED₅₀ ED₅₀ Spon- AD₅₀ (μg/kg) (hill (hill Tail Hot Hypo- taneousTail Hot slope) slope) Flick Plate thermia Activity Flick PlateComparative compounds Nicotine 1.50 ± 0.30 1.3  0.65  1.0  0.5 (0.5-1.8) (0.25-0.85) (0.6-2.1) (0.15-0.78) (−)-epibatidine 0.018 ±0.001 0.006 0.004 0.004 0.001 (0.001-0.01)  (0.001-0.008) (0.002-0.008)(0.0005-0.005)  varenicline 0.12 ± 0.02 32.5 ± 1.3  11% @ 10 10% @ 102.8  2.1  0.2  470 Inventive Compounds X H 0.12 ± 0.02 32.5 ± 1.3  1.5 1.63  0.6  0.32  15% @ 100  0% @ 100 (1.2-2)     (1-2.6) (0.16-2)  (0.2-0.5) F 0.84 ± 0.08 1927 2.15  1.2  0.25  0.15  0.24 33% @ 100 n =1  (1.7-2.7) (0.8-1.7) (0.13-0.47) (0.03-0.57) (0.13-0.43) Cl 0.32 ±0.09 170 ± 64  0.28  0.25  0.03  0.027  5% @ 100  2% @ 100 n = 2*(0.17-0.45) (0.15-0.43)  (0.02-0.035) (0.01-0.04)

1-11. (canceled)
 12. A compound according to the structure:

wherein: A is —R, —N(R)₂, —C(═NR)N(R)₂, or —OR, each R is,independently, H, alkyl, alkenyl, alkynyl, aryl, or aralkyl; each X is,independently, H, halo, alkyl, alkenyl, alkynyl, aralkyl, —OR,—CH₂—CO₂R, —C(O)R, —CO₂R, —N(R)₂, —NR—C(O)R, —C(O)N(R)₂, —NR—CO₂R,—SO₃CF₃, —NO₂, —N₃, —CF₃, —CH═CHY, or —CN; Y is halo; n is an integerfrom 0-3; and R₁ is a substituted pyridine having one or moresubstituents including at least one CONR₁₂R₁₃ substituent, wherein R₁₂and R₁₃ are independently selected from H and C1-10 alkyl; or apharmaceutically acceptable salt or stereoisomer thereof.
 13. A compoundof claim 12, wherein the compound has the following structure:

wherein: each R₂ is independently selected from the group consisting ofH, C1-6 alkoxy, amino, halo, hydroxyl, CONR₁₂R₁₃, CN, CH₃SO₂, andCF₃SO₂, wherein R₁₂ and R₁₃ are independently selected from H and C1-10alkyl; each X is independently H or halo; and m is an integer from 1-4;wherein at least one R₂ substituent is CONR₁₂R₁₃; or a pharmaceuticallyacceptable salt or stereoisomer thereof.
 14. A compound of claim 12,wherein the compound has the following structure:

wherein: each R₂ is independently selected from the group consisting ofH, C1-6 alkoxy, amino, halo, hydroxyl, CONR₁₂R₁₃, CN, CH₃SO₂, andCF₃SO₂, wherein R₁₂ and R₁₃ are independently selected from H and C1-10alkyl; each X is independently H or halo; and m is an integer from 1-4;wherein at least one R₂ substituent is CONR₁₂R₁₃; or a pharmaceuticallyacceptable salt or stereoisomer thereof.
 15. The compound of claim 13,wherein m=1 and the R₂ substituent is located on the carbon adjacent tothe N of the ring and para to the remainder of the molecule.
 16. Thecompound of claim 14, wherein m=1 and the R₂ substituent is located on acarbon adjacent to the N.
 17. The compound of claim 12, wherein the R₁₂and R₁₃ substituents are both H.
 18. The compound of claim 13, whereinthe R₁₂ and R₁₃ substituents are both H.
 19. The compound of claim 14,wherein the R₁₂ and R₁₃ substituents are both H.
 20. The compound ofclaim 12, wherein n=1 and the X substituent is a chloro or fluoro group.21. The compound of claim 13, wherein n=1 and the X substituent is achloro or fluoro group.
 22. The compound of claim 14, wherein n=1 andthe X substituent is a chloro or fluoro group.
 23. A method for treatingor delaying the progression of addiction or depression, the methodcomprising administering a therapeutically effective amount of acompound of claim
 12. 24. The method of claim 23, wherein the addictionis addiction to nicotine.
 25. A method for treating or delaying theprogression of addiction or depression, the method comprisingadministering a therapeutically effective amount of a compound of claim13.
 26. The method of claim 25, wherein the addiction is addiction tonicotine.
 27. A method for treating or delaying the progression ofaddiction or depression, the method comprising administering atherapeutically effective amount of a compound of claim
 14. 28. Themethod of claim 27, wherein the addiction is addiction to nicotine. 29.A pharmaceutical composition comprising a compound of claim 12 and oneor more pharmaceutically acceptable carriers.
 30. A pharmaceuticalcomposition comprising a compound of claim 13 and one or morepharmaceutically acceptable carriers.
 31. A pharmaceutical compositioncomprising a compound of claim 14 and one or more pharmaceuticallyacceptable carriers.